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Type 1 diabetes mellitus is a chronic inflammatory disease in which the insulin 
and glutamic acid decarboxylase producing β-cells of the pancreatic islets are killed by 
autoreactive cells of the immune system in response to a loss of tolerance. Early 
experiments showed that self-tolerance could be partially restored by oral inoculation 
with small amounts of insulin. Later experiments showed that insulin autoantigen induced 
immune tolerance could be greatly enhanced by linkage of β-cell autoantigens (Auto Ag) 
to adjuvant molecules such as the non-toxic cholera enterotoxin B subunit (CTB).   
To identify mechanisms responsible for CTB-autoantigen fusion protein 
suppression of diabetes autoimmunity, dendritic cells (DCs), a major class of antigen 
presenting cells (APC) involved in restoration of immunological tolerance, were 
differentiated from umbilical cord blood monocytes and incubated with recombinant 
CTB- pro-insulin and CTB-glutamic acid decarboxylase adjuvant-autoantigen fusion 
proteins. The fusion proteins were shown to dramatically suppress DC biosynthesis of 
costimulatory factors and proinflammatory cytokines IL-12 and IL-6 required for 
autoreactive T cell development. In addition, a substantial increase in DC secretion of the 
anti-inflammatory cytokine IL-10 was also detected further confirming the previous 
xxii 
observation. Naïve T cells incubated with CTB-autoantigen inoculated DCs developed 
into mature T cells that synthesized IL-10 and TGF-β cytokines indicative of Th2, Tr1 
and Th3 regulatory T cell populations involved in suppression of CD4+ and CD8+ T 
lymphocytes responsible for the initiation of diabetes autoimmunity.  Further, vaccine 
inoculated DCs suppressed T cell pro-inflammatory cytokines IFN-γ, IL-17 and IL-2 
guiding T cell morphogenesis in the direction of tolerance rather than toward 
inflammation responsible for diabetes onset. In summary: the experimental results 
presented in this Dissertation indicate that ex vivo vaccination of human DCs favors 
immunological suppression of diabetes development and suggests that mechanisms of 
immunological tolerance responsible for multicomponent vaccine suppression of diabetes 
onset and possibly progression are comparable in humans and in animals.     
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CHAPTER ONE 
INTRODUCTION 
 
Type 1 Diabetes 
Diabetes Etiology 
Juvenile onset autoimmune diabetes also known as type 1 diabetes (T1D) or 
insulin-dependent diabetes mellitus (IDDM) is considered to be the most serious 
metabolic disease of children and adolescents. High blood sugar (hyperglycemia) and 
inflammation of the pancreatic islets (insulitis) result from a breakdown in 
immunological homeostasis leading to loss of immunological tolerance. Consequently, 
the pancreatic islets of Langerhans insulin-producing β-cells are destroyed by the body’s 
immune system gone rogue. Chronic insulitis and progressive β-cell death are initiated by 
islet autoantigen stimulated maturation of antigen-presenting cells, largely dendritic cells 
(DC) part of the host innate arm of the immune system.  Autoantigen activated DCs 
migrate to pancreatic and other peripheral lymph nodes where they induce naïve T 
lymphocyte (Th0) development into autoreactive CD4+ T helper cell and CD8+ cytotoxic 
T lymphocytes, as well as B cells that synthesize autoreactive antibodies (Atkinson, 
Bowman et al. 1994; Atkinson and Maclaren 1994; Tisch and McDevitt 1996; Han, Serra 
et al. 2005). The progressive loss of β-cell function causes increased insulin deficiency 
eventually resulting in the onset and progression of hyperglycemia, (frank diabetes) (Fig 
1.1).  
 Young and older T1D patients alike must monitor their blood sugar levels and 
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inject insulin several times a day for the remainder of their lives or risk diabetic shock, 
coma and death. While daily multiple insulin injections suppress diabetes symptoms, this 
therapy does not provide consistent physiological levels of insulin. Without insulin, there 
is a problem of chronic glucose dysregulation resulting in unacceptable levels of 
disability and mortality. Symptoms of hyperglycemia include, but are not limited to, 
frequent thirst and urination as the kidneys attempt to cope with efforts at eliminating 
excess sugar from the bloodstream.  In addition, extreme hunger, weight loss, fatigue, and 
blurred vision may occur due to cellular glucose deprivation. Long-term complications 
include a progressive risk for neural and circulatory failure resulting in amputation of the 
extremities, blindness, kidney failure, heart attack and stroke reducing average life 
expectancy by an average of 15 - 20 years (Libby, Nathan et al. 2005). See Table 1.1.  
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Table 1.1.  Secondary Effects of Diabetes Onset from Diabetes Health Statistics (U.S.A.) 
Heart disease 
and stroke 
• Heart disease and stroke account for about 65 percent of deaths in 
people with diabetes. 
• Adults with diabetes have heart disease and stroke death rates about 
2 to 4 times higher than adults without diabetes. 
High Blood 
Pressure 
• About 75 percent of adults with diabetes have blood pressure greater 
than or equal to 130/80 mm Hg or use prescription medications for 
suppressing hypertension. 
Blindness 
• Diabetes is the leading cause of new cases of blindness among 
adults aged 20 to 74 years. 
• Diabetic retinopathy causes 12,000 to 24,000 new cases of blindness 
each year. 
Kidney 
Disease 
• Diabetes is the leading cause of kidney failure, accounting for 44 
percent of new cases in 2005. 
• In 2005, 46,739 people with diabetes began treatment for end-stage 
kidney disease in the United States and Puerto Rico while 178,689 
people had end-stage kidney disease that required chronic dialysis or 
kidney transplantation. 
Nervous 
System 
Disease 
• About 60 to 70 percent of people with diabetes have mild to severe 
forms of nervous system damage.  The results of such damage 
include impaired sensation or pain in the feet or hands, slowed 
digestion of food in the stomach, carpal tunnel syndrome, erectile 
dysfunction, or other neuropathological problems. 
• Almost 30 percent of people with diabetes ages 40 years or older 
have impaired sensation in the feet—for example, at least one area 
that lacks feeling. 
• Severe forms of diabetic nerve disease are a major contributing 
cause of lower-extremity amputations. 
Amputations 
• More than 60 percent of non-traumatic lower-limb amputations 
occur among people with diabetes. 
• In 2004, about 71,000 non-traumatic lower-limb amputations were 
performed in people with diabetes. 
Dental 
Disease 
• Periodontal or degenerative gum, disease is more common in people 
with diabetes.  Among young adults, those with diabetes have about 
twice the risk as those without diabetes. 
• People with poorly controlled diabetes—A1C greater than 9 
percent—were nearly three times more likely to have severe 
periodontitis than those without diabetes. 
• Almost one-third of people with diabetes have severe periodontal 
disease with loss of attachment of the gums to the teeth measuring 5 
millimeters or more. 
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Table 1.1.  Continued. 
Complications 
of Pregnancy 
• Poorly controlled diabetes before conception and during the first 
trimester of pregnancy among women with T1D can cause major 
birth defects in 5 to 10 percent of pregnancies and spontaneous 
abortions in 15 to 20 percent of pregnancies. 
• Poorly controlled diabetes during the second and third trimesters of 
pregnancy can result in excessively large babies, posing a risk to 
both mother and child during delivery. 
Other 
Complications 
• Uncontrolled diabetes often leads to biochemical imbalances that 
can cause acute life-threatening events, such as diabetic ketoacidosis 
and hyperosmolar, or nonketotic, coma. 
• People with diabetes are more susceptible to many other illnesses 
and, once they acquire these illnesses, often have worse prognoses.  
For example, they are more likely to die with pneumonia or 
influenza than people who do not have diabetes. 
• People with diabetes ages 60 years or older are two to three times 
more likely to report an inability to walk a quarter of a mile, climb 
stairs, do housework, or use a mobility aid compared with people 
without diabetes in the same age group. 
Health 
Disparities 
• Non-Hispanic white youth had the highest rate of new cases of type 
1 diabetes—24.8 per 100,000 per year among those younger than 10 
years and 22.6 per 100,000 per year among those ages 10–19 years 
(Source: SEARCH for Diabetes in Youth Study 2002-2005) 
Source: http://diabetes.niddk.nih.gov/DM/PUBS/statistics/ 
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Figure 1.1. Basic Mechanism of Type 1 Diabetes Inflammation and Vaccine Action  
Antigen presenting cells, more specifically dendritic cells, process endogenous pancreatic 
beta cell autoantigens (Insulin, GAD…) in lysosomal vesicles and transfer peptide 
fragments of the autoantigen to MHCII molecules that migrate to the plasma membrane 
and present the autoantigen fragments to cognate T cell receptors on naïve T helper cells 
(Th0), left portion of Figure 1.1.  Dendritic cell processing of the autoantigen stimulates 
biosynthesis and secretion of the inflammatory cytokine interleukin 12 (IL-12) which 
stimulates naive Th0 lymphocytes to undergo morphogenesis into autoreactive effector T 
helper cells (Th1). The autoreactiveTh1 cells secrete inflammatory cytokines such as 
IFN-gamma and IL-2 that stimulate cytotoxic lymphocytes (CTL) to secrete nitric acid, 
peroxide and several additional inflammatory cytokines such as TNF-α and IL-1 β that 
stimulate pancreatic islet inflammation (insulitis). Chronic insulitis results in progressive 
pancreatic beta cell death resulting in an increasing insulin deficiency and a progressive 
increase in blood sugar (hyperglycemia). Oral delivery of small amounts of islet 
autoantigens (right portion of panel); exert a specific protective antigen therapeutic effect 
by stimulating dendritic cell secretion of the anti-inflammatory cytokine IL-10.  Secretion 
of IL-10 stimulates naïve cognate naïve Th0 lymphocytes to undergo morphogenesis into 
anti-inflammatory CD4+ Th2 helper cells that in turn secrete IL-10, which suppresses 
autoreactive Th1 cell development and decreases the potential for insulitis onset. 
Alternatively, naive Th0 cells may develop into one of several subclasses of regulatory T 
cells (Treg), which can block dendritic cell activation, Th2, Th1 and CTL development 
leading to prevention of insulitis, continued insulin secretion and maintenance of 
immunological homeostasis (Ploix, Bergerot et al. 1999; Liu, Iyoda et al. 2002). 
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Epidemiology of Type 1 Diabetes 
  According to the National Institutes of Diabetes and Digestive and Kidney 
Diseases-NIDDK, the current incidence rate of TID in the U.S is approximately 19.7 per 
100,000 annually. Among youth ages 10 years or older, the incidence rate is 18.6 per 
100,000 children (National Diabetes Statistics Fact Sheet, 2010).  Stratified by race and 
ethnicity, non-Hispanic white youth had the highest rate of new cases of TID with 24.8 
cases per 100,000 per year among those younger than 10 years and 22.6 cases per 
100,000 per year among those of ages 10–19 years (National Diabetes Statistics Fact 
Sheet, 2010). Worldwide, it is estimated that there are 65,000 newly diagnosed cases of 
T1D per year for children less than 15 years of age (source:  International Diabetes 
Federation, 2009).  Over the past 50 years, T1D prevalence has experienced an 
exponential rise, which seemingly has more to do with environmental factors than genetic 
causation (Gillespie, Bain et al. 2004). Worldwide, the incidence of T1D in children 
under 14 yr has increased on all continents except Central America and the West Indies 
from 1990 – 1999 (2006).  In this study of 43,013 cases of T1D out of a population size 
of 84 million (representing 114 populations in 57 countries), the average rise in incidence 
of T1D from 1990 to 1994 was 2.4%.  From 1995 to 1999 the worldwide incidence rose 
to 3.4%. Figure 1.2 shows the worldwide incidence of Type 1 diabetes in children ≤14 
years of age. 
 In a large longitudinal study conducted in 17 European countries and based on 
current T1D statistics, it is predicted that between the years 2005 and 2020, new cases of 
T1D in European children younger than five years of age will double, while the 
prevalence of T1D is expected to rise by 70% to 160,000 cases in children under fifteen 
8 
Type 1 diabetes incidence per 100,000/year 
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Figure 1.2: Worldwide incidence of Type 1 diabetes in children ≤14 years of age. 
Values presented are age-adjusted and listed in descending order of incidence (per 
100,000 people per year).  Note that many of the countries with the highest incidence of 
diabetes are located north or south of the equatorial belt, where sunshine is less intense 
annually and therefore dermal vitamin D synthesis is lower, on average, suggesting a role 
for vitamin D in diabetes onset.  Other countries with a high incidence of people with 
T1D are industrialized nations, where children and adults spend more time indoors and 
out of the sun.  Despite being in a sunny location, apparent anomalies like Kuwait—the 
country with the 4th highest incidence of T1D—might have increased numbers of people 
with autoimmune diabetes due to their darker skin color and a tendency to clad 
themselves extensively in clothes that may block vitamin D synthesis. 
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years (Patterson, Dahlquist et al. 2009). The disparity between T1D prevalence and 
incidence across the globe may be explained by a multi-factorial and complex 
combination of factors involving population genetics, socioeconomic status, exposure to 
pathogens, geographic location, skin color (melanin density), diet (e.g. vitamin D 
supplementation, consumption of cow’s milk, nitrates, etc.) and genetics. 
The first sign of disease onset in patients with T1D is the presence of autoantibodies 
produced by self-reactive B-cells.   Serological analyses showed that some children 
develop autoantibodies as early as three months of age (Kukko, Kimpimaki et al. 2005). 
In T1D patients, the number of autoantibodies to insulin (INS), glutamic acid 
decarboxylase (GAD), or islet cell autoantigen-512 (ICA512) is indicative of the relative 
risk for development of diabetes among first-degree relatives (Verge, Gianani et al. 1996; 
Verge, Gianani et al. 1996).  The five-year risk of a diabetes outcome was as follows:   
No positive islet autoantibodies = 0%; 
Presence of autoantibodies to one islet autoantigen = 15%; 
Presence of autoantibodies to two islet autoantigens = 44%; 
Presence of autoantibodies to three islet autoantigens = 100% risk. 
Anti-INS antibodies can be found in 50-70% of T1D children (Greenbaum, Palmer et 
al. 1992) and anti-IA-2 antibodies are seen in 70-80% of cases (Gorus, Goubert et al. 
1997).  Anti-GAD antibodies occur in 70-75% of T1D patients. However, it was found 
that 1-2% of the general population generates anti-GAD antibodies yet still retains 
normal pancreatic function (Sanjeevi, Falorni et al. 1996).  This observation suggests that 
autoreactive lymphocytes may be present in healthy individuals, but may be down 
regulated by tolerogenic mechanisms after they escape thymic selection early in life. 
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Disease onset due to hyperglycemia (>250 mg/dl blood glucose), can take years to 
develop following initial detection of autoantibodies (Eisenbarth 1986).  While 
autoantibodies produced by B-cells are indicative of disease onset, they are not thought to 
serve a pathogenic role (Yoon and Jun 2005).  The main role of B-cells in pancreatic islet 
beta cell destruction may be related to their ability to present β-cell antigens to 
autoreactive T-cells, which in turn activates cytotoxic lymphocyte destruction of the β-
cells.  Hyperglycemia, the major clinical symptom of overt diabetes, occurs only after 
>80-90% of the insulin-producing β-cells have been destroyed by cytotoxic T-
lymphocytes and macrophages (Knip and Siljander 2008).  Although β-cell destruction 
continues throughout the lifetime of the T1D patient, it appears that insulin-producing 
cells continue to be differentiated to a small degree within the pancreas and can still be 
detected in >88% of patients with frank diabetes (Meier, Bhushan et al. 2005).  This 
condition suggests that if a targeted immune suppression therapy such as that proposed in 
this dissertation was to be applied, newly formed β-cells could be protected from 
autoimmune destruction, resulting in improved possibility for restoration of 
normoglycemia.  Islet transplant or stem cell therapy may supplement and even 
accelerate the regeneration of islet beta cells, but only if autoreactive lymphocyte activity 
can be persistently blocked to prevent their destruction of nascent β-cells.   
 
Factors Affecting the Etiology of Type 1 Diabetes 
Genetics 
Haplotype differences in the major histocompatibility complex (MHC) genes 
responsible for self-antigen presentation to the immune system may account for many 
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individuals with increased susceptibility to autoimmunity.  Specifically as it applies to 
TID, disease susceptibility is determined by variations in the HLA-DQ (an 
αβ heterodimer of the MHC class II cell surface receptor found on antigen presenting 
cells) on chromosome 6 beta genes, while additional alleles provide significant resistance 
to T1D development (Todd, Bell et al. 1987).  More recently, a genome-wide search 
identified alleles at 41 loci that increase the risk of T1D development, including 
variations in several important interleukin (IL) genes and surface markers involved in 
immune activity or β-cell function such as IL10, IL19, IL20, GLIS3, CD69 and IL27 
(Barrett, Clayton et al. 2009).   
In some cases, random genetic recombination of T-cell receptor (TCR) genes for T-
cell specific antigenic epitope recognition can result in TCRs that bind self-peptides.  
Normally, autoreactive T-cells are selected and eliminated in the thymus (thymic 
selection).  However, it is possible that some of these autoimmunity-stimulating T-cells 
may escape this process and become suppressed by regulatory immune cells located in 
the periphery of healthy individuals.  In autoimmune disease victims, the regulatory 
capacity of the immune system is no longer able to downregulate autoreactive T-cell 
development.  The majority of epitopes responsible for induction of TID autoimmunity 
are fragments of proinsulin —INS (Palmer, Asplin et al. 1983), glutamic acid 
decarboxylase—GAD (Baekkeskov, Aanstoot et al. 1990), insulinoma associated 
autoantigen-2 (IA-2 and IA-2β/phogrin) (Bonifacio, Lampasona et al. 1995; Lu, Li et al. 
1996), carboxypeptidase-H (Castano, Russo et al. 1991), islet cell autoantigen-69—
ICA69 (Pietropaolo, Castano et al. 1993), GM gangliosides (Nayak, Omar et al. 1985), 
imogen-38 (Arden, Roep et al. 1996), sex-determining region Y-related protein-13—
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SOX13 (Kasimiotis, Myers et al. 2000). A compilation of the predominant epitopes 
recognized by CD4 and CD8 T-cells from humans and mice with TID has been published 
by Di Lorenzo, T.P. et al. (2007). Recently, autoantibodies to zinc transporter protein— 
ZnT8 were found in 60 – 80% of patients with new onset T1D, including 26% that 
uniquely had ZnT8 antibodies in the absence of antibodies that recognize the usual 
markers of β-cell autoimmunity—INS, GAD, IA-2, and ICA (Wenzlau, Juhl et al. 2007).  
Detection of T1D at disease onset was achieved in 98% of individuals when antibodies 
were screened against a combination of INS, GAD, IA-1, and ZnT8 proteins.   
 
Molecular Mimicry 
 Since genetics alone only accounts for approximately 50% of diagnosed T1D 
cases, environmental influences on disease initiation cannot be ignored (Drescher and 
Tracy 2008).   Although poorly developed, there is increasing evidence that exposure to 
certain pathogens may increase susceptibility to TID.  Particularly, molecular mimicry, 
epitope spreading, or direct bystander activation by pathogen epitopes with similar 
structure or binding capacity to human proteins may lead to cross-reactive antibody or T-
cell receptor formation that can trigger an immune attack against self-tissues (Olson, 
Croxford et al. 2001).  To date, 14 different viruses have been reported that may be 
strongly associated with T1D in humans and various animal models (Jun and Yoon 
2003). The Coxsackie B enterovirus (a member of the picornaviridae) is one of the 
viruses most suspected of eliciting a cross-reactive immune response (Drescher and 
Tracy 2008).  
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Immune Suppression of Diabetes Autoimmunity 
Dendritic Cells are Sensors of Infection and Activate T cells in 
Peripheral Lymphoid Organs 
 Dendritic cells (antigen presenting cells that bridge the innate and adaptive arms 
of the immune system); continuously patrol the microenvironment for invading 
pathogens. DCs are not a single cell type, but a heterogeneous collection of cells that 
arise from distinct, bone marrow-derived or hematopoietic lineages (Caux, Massacrier et 
al. 1997; Reid 1997). That is, subsets from different tissues have been shown to possess a 
differential morphology, phenotype and function (Appendix 5). Three-color flow 
cytometry revealed two subpopulations of HLA-DR+ DCs, characterized primarily by the 
phenotypes CD11c- HLA-DR+ (lymphoid appearance) and CD11c+ HLA-DR+ 
(monocytoid morphology) respectively (Thomas and Lipsky 1994; Robinson, Patterson et 
al. 1999).  Further, both subsets lack expression of the LC marker CD1a and express only 
low levels of adhesion and co-stimulation molecules CD80, CD86 and CD40, suggesting 
that these cells are relatively immature (Carnevali, Bonati et al. 1980; O'Doherty, Peng et 
al. 1994; Robinson, Patterson et al. 1999). However, when cultured, both populations 
develop into cells with typical DC morphology that express high levels of adhesion and 
co-stimulatory molecules and possess potent allostimulatory function (O'Doherty, Peng et 
al. 1994). It has been suggested that the so-called myeloid and lymphoid-derived subsets 
of DCs perform specific stimulatory or tolerogenic function, respectively. Regardless of 
their subset, the ability to stimulate naïve T cell proliferation appears to be shared 
between these various DC subsets (Hart 1997; Shortman and Caux 1997). DCs become 
activated by inflammatory or pathogenic products derived from microbes, toxins or from 
damaged tissues (Viney 2001).  The acquired stimulus induces DC mobilization from 
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non-lymphoid tissues to draining lymphoid organs via afferent lymphatic vessels.  DCs 
are thought to exist either in an immature or mature state.  The capacity of DCs to induce 
immunity depends on their state of development frequently referred to as “maturation” 
(Figure 1.3).  During maturation, the DCs convert antigens to immunogens, which they 
transfer via MHC molecules from intracellular vesicles to the cell surface. In addition 
during activation, DCs express adhesion and co-stimulatory molecules (e.g. CD86, 
CD80, CD83 and CD40), for establishment of cell-to-cell interactions and the release of 
soluble cytokines, chemokines and enzymes responsible for regulating cellular 
communication and mobilization (Banchereau and Steinman 1998; de Saint-Vis, Fugier-
Vivier et al. 1998; Guermonprez, Valladeau et al. 2002; Jiao, Lo-Man et al. 2002). 
Immature DCs are characterized by very low levels of synthesis and membrane 
presentation of surface co-stimulatory molecules and by low levels of IL-6, IL-1β, TNF-α 
and IL-12 inflammatory cytokine biosynthesis (Hackstein and Thomson 2004). In 
contrast, DC maturation triggers an increase in the expression of inflammatory cytokines. 
DCs become terminally matured when they finally make contact with cognate T 
lymphocytes in the specialized microenvironment of lymph node tissues, which permits 
intimate physical interaction among DCs and naïve T lymphocytes referred to as the 
immunologic synapse (Merwe 2002; Gogolak, Rethi et al. 2003). Primarily, DCs function 
as specialized cellular sensors of pathogenic changes that occur within a tissue. In 
addition to detection of pathogenic changes, a second major DC function is transmission 
of this information to cognate T lymphocytes for further processing leading to an 
amplified immune response (Reis e Sousa 2001).  The immunological synapse formed 
between the DC and the T cell is stabilized by multiple co-stimulatory and adhesive 
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Figure 1.3. The antigen presentation and T cell activation functions of mature dendritic 
cells.  
Differentiated (mature) dendritic cells are professional antigen presenting cells located in 
tissues throughout the body and especially adjacent to the epidermal mucosae.  Mature 
DCs are able to activate both CD4+ helper and CD8+ cytotoxic T lymphocytes based on 
the nature of the pathogen proteins taken up and processed by the antigen-presenting 
cell. Helper T lymphocytes can also support B cell differentiation and antibody 
production (Gogolak, Rethi et al. 2003) 
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 molecules, while the immunological specificity of the signaling complex is maintained 
by interactions between the MHC-Peptide –TCR complex (Figure 1.3). The expression 
of co-stimulatory molecules and cytokine receptors on DCs in combination with the 
pattern of DC released cytokines are responsible for differentiation of the naïve CD4+ 
helper T lymphocyte component into either a Th1 or Th2 effector cell (Itano and Jenkins 
2003). Naïve T cells are known to differentiate into immunostimulatory Th1 cells in the 
presence of the DC secreted pro-inflammatory cytokine IL-12. Alternatively Th0 cells 
develop into immunosuppressive Th2 cells in the presence of DC secreted 
immunotolerizing cytokines IL-4 and IL-10.  The Th1 lymphocyte subtype secretes 
inflammatory cytokines such as IL-2 and IFN-γ. These Th1 cells can also support the 
priming of CD8+ cytotoxic T lymphocytes (CTL), (De Smedt, Butz et al. 2001; 
Maldonado-Lopez, Maliszewski et al. 2001; Maldonado-Lopez and Moser 2001). 
Alternatively, Th2 lymphocytes secrete IL-4, IL-10 and TGF-β (Lutz and Schuler 2002). 
DCs can also determine the differentiation of naïve T cells into regulatory T cells (Tregs), 
(Levings, Sangregorio et al. 2001; Roncarolo, Bacchetta et al. 2001; Roncarolo, Levings 
et al. 2001). Research has shown that Treg cells can suppress DC maturation resulting in 
maintenance of the immunosuppressive, less mature DC phenotype (Mahnke, Johnson et 
al. 2007).  
 
The Role of Toll like Receptors in Immune Suppression 
To maintain immunological homeostasis, DCs, macrophages and B cells 
recognize pathogen antigens and autoantigens in the periphery by binding conserved 
pathogen associated molecular patterns (PAMPS), to trans-membrane Toll-like receptor 
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(TLR) domains (Takeda and Akira 2001; Takeda and Akira 2003; Wen, Peng et al. 
2004). Different PAMPS stimulate specific TLRs activating DC signal transduction 
pathways through adaptor proteins (e.g., MyD88), leading to synthesis or stimulation of 
transcriptional activators e.g., nuclear factor kB (NFkB), mitogen activated protein 
kinases (MAPKs), c-Jun N-terminal kinase (JNK) and interferon regulatory factor 3 
(IRF3). These transcriptional activators initiate expression of genes encoding specific 
cytokines (IL-12, IL-10), costimulatory molecules and chemokines that enable antigen 
activated DCs to guide the development of naïve Th0 cell into immunoreactive Th1 cells, 
Th2 immunosuppressive effector cells or regulatory T cell subsets (Kaisho and Akira 
2001; Kaisho and Akira 2002). Further, TLR agonists can break immunological tolerance 
and induce autoimmune diseases such as arthritis (Deng, Nilsson et al. 1999), 
experimental autoimmune encephalomyelitis (EAE) (Segal, Chang et al. 2000) and 
diabetes (Lang, Recher et al. 2005). While most TLR agonists are potent adjuvants that 
promote the development of inflammatory Th1 effector cells, a number of reports show 
that TLR stimulation may also suppress autoimmune pathogenesis, suggesting a dual role 
for TLRs in autoimmune diseases (see review by Ehlers and Ravetch, 2007). On 
occasion, the dual role of TLRs can be demonstrated in the same model, but using 
different routes of ligand administration. For example, intravenous injection of the TLR9 
ligand CpG together with ovalbumin resulted in the induction of tolerance in vivo. 
However, following subcutaneous injection, the same ligands induced inflammation 
(Wingender, Garbi et al. 2006). Further, it was demonstrated that TLR2 ligands drive 
induction of Th2 lymphocyte populations that stimulate immunosuppression, (Hemmi, 
Takeuchi et al. 2000; Bauer, Kirschning et al. 2001; Kapsenberg 2003; Dillon, Agrawal 
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et al. 2004; Jarnicki, Conroy et al. 2008; Agrawal S 2003) and modulate the functions of 
CD4+CD25+ regulatory T cells (Liu, Liao et al. 2006). Recently, examination of TLR2 
and TLR4 expression in monocytes from T1D patients showed that TLR2 and TLR4 
surface expression and mRNAs were significantly increased in T1D monocytes in 
comparison with the controls (Devaraj, Dasu et al. 2008). Downstream transcriptional 
activator and adaptor proteins NF-κB, MyD88, Trif and pIRAK, were also significantly 
upregulated suggesting DC activation is involved in immune suppression of T1D. 
Agonists of TLR-4 or TLR-9 can also inhibit autoimmune diseases, such as EAE, 
arthritis, diabetes, ulcerative colitis and systemic lupus erythematosus (SLE) in mice 
(Gilkeson, Ruiz et al. 1996; Rachmilewitz, Karmeli et al. 2002; Alyanakian, Grela et al. 
2006; Buenafe and Bourdette 2007). Autoreactive T cells involved in EAE and other 
chronic inflammatory autoimmune diseases are considered to follow defined TLR 
pathways of DC processing and autoantigen presentation triggered by environment 
signals (Haverkos, Battula et al. 2003; Ylipaasto, Klingel et al. 2004; Bach 2005). 
Signaling through TLRs 3 and 7 exacerbates autoimmune diabetes in a mouse model, and 
the effect is mediated by IFN-α (Lang, Recher et al. 2005).   
 
Dendritic Cell Costimulatory Molecules CD86 (B7-2) and CD83 are 
Essential for Efficient CD4+ T helper Lymphocyte Activation 
Unlike other antigen presenting cells, DCs have a unique capacity to present 
peptides via MHC class II molecules during maturation, pointing to complex multilevel 
regulation of antigen presentation by mature DC (Gogolak, Rethi et al. 2003). Activation 
of naïve Th0 lymphocytes requires engagement of the TCR with the MHC class II - 
antigen peptide complex presented on the DC plasma membrane surface (Bromley, 
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Iaboni et al. 2001).  DCs can acquire external antigens from the environment; process 
them within specialized MHC class II rich compartments within the DC as a result of 
activation and maturation. This initial DC processing induces the transport of antigen 
peptide loaded MHC class II molecules to the plasma membrane. The capacity of the DC 
to transport the MHC class II –antigen peptide complex to the cell membrane is 
dependent upon co-transport of the antigen along with the CD86 co-stimulatory factor 
protein which together provides efficient activation of CD4+ helper T cells (Inaba, Turley 
et al. 1998; Inaba, Turley et al. 2000; Turley, Inaba et al. 2000). In addition to antigen 
specific interactions mediated by the MHC II peptide complex, a second protein 
interaction involving CD28 originating on T cells and its respective DC ligand CD86 
(B7-2), which exists as a monomer on the APC, is required for optimal T cell activation 
(Carreno and Collins 2002; Collins, Ling et al. 2005).  
The cluster of differentiation molecule CD83 is a type-1 membrane glycoprotein 
of the Ig superfamily expressed by most DCs, including thymic DCs, skin Langerhan’s 
cells, circulating DCs, interdigitating reticulum cells present in the T cell zones of 
lymphoid organs and monocyte derived DCs (Zhou, Schwarting et al. 1992; Weissman, 
Li et al. 1995; Zhou and Tedder 1995; Zhou and Tedder 1995; Zhou and Tedder 1996). 
The CD83 protein is considered to be a marker of DC maturation. The fact that CD83 
biosynthesis is strongly upregulated together with co-stimulatory molecules CD80 and 
CD86 during DC maturation suggests CD83 plays an important role in the induction of 
immune responses. Infection studies with herpes simplex virus type 1 (HSV-1) and the 
inhibition of CD83 mRNA specific transport from the nucleus to the cytoplasm suggests 
a possible functional role for CD83 (Lechmann, Zinser et al. 2002). The first clear proof 
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that CD83 is indeed important for DC biology came from recently performed studies 
employing a soluble form of the extracellular CD83 domain to inhibit DC-mediated T 
cell proliferation (Lechmann, Kremmer et al. 2002). Additional studies elucidated 
immunostimulatory as well as regulatory effects of the CD83 molecule (Lechmann, 
Berchtold et al. 2002; Lechmann, Zinser et al. 2002; Kuwano, Prazma et al. 2007). These 
studies revealed that CD4+ T cell generation was blocked in CD83-/- knockout mice.  
 
The Role of CD4 and CD8 T Lymphocytes in Type 1 Diabetes 
Pathogenesis 
T cells specifically provide immune protection by activating macrophages and 
stimulating neutrophil migration to sites of infection, in addition to inducing B cell antibody 
production (Zhu and Paul 2008).  
 T lymphocytes exist as a heterogeneous population of CD4+ helper or CD8+ 
CTLs. However, each T lymphocyte cell type is subdivided into distinct subpopulations. 
The CD4 lymphocytes are considered to be largely the sole player in the induction of 
autoimmune annihilation of islet beta cells for the following reasons: 1) in animal models 
of T1D, CD4 cells were abundantly identified in islet cell infiltrates.  2) Lymphocyte 
transfer studies suggested that isolation of CD4 T cells from diabetic NOD mice could 
transfer diabetes into disease free animals (Haskins, Portas et al. 1988). 3) Defective 
genes involved T1D were mapped within the same region of the MHC for expression of 
class II polypeptides that specifically interact with CD4. Together, these findings 
suggested that the autoimmune pathology was caused by rogue T cells escaping into the 
circulation as a result of faulty positive T cell selection following presentation with 
diabetogenic peptides (Faustman and Davis 2009). Alternatively, CD8 cells were not 
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actively considered to play a significant role in T1D because their functions were thought 
to be limited to fighting foreign antigens such as viruses. However, there is an increasing 
body of evidence arising from monozygotic twin and NOD mouse studies of T cell 
education that implicate CD8+ T cells in the pathogenesis of T1D (Faustman, Li et al. 
1991; Li, Guo et al. 1994; Faustman and Davis 2009). Other murine and human studies 
have expanded the role of class I polypeptide presentation of antigens, from providing 
protection against viral antigens, to protecting against both viral and self antigens. These 
results directly implicate poorly educated CD8 T cells in the destruction of beta cells 
expressing self peptides in the class I MHC polypeptide groves (Faustman, Li et al. 1991; 
Yan, Shi et al. 1997; Faustman and Davis 2009).   
 
Lymphocyte Subsets Th17 and Tc17 Produce the Inflammatory 
Cytokine IL-17 
Both CD4+ Th17 cells and CD8+ Tc17 cells are two recently described T lymphocyte 
subsets that are mainly characterized based on their ability to produce the 
proinflammatory cytokine IL-17.  The Th17 lymphocyte subset constitutes a third group 
of effector T lymphocytes (in addition to Th1 and Th2 cells), found to be associated with 
autoimmunity (Harrington, Hatton et al. 2005).  In addition to the production of IL-17, 
IL-21, and IL-22 (Bettelli, Oukka et al. 2007), Th17 cells are also distinguished by their 
expression of the transcription factor retinoic acid, orphan receptor gamma—ROR-γt 
(Ivanov, McKenzie et al. 2006).  The Th17 lymphocyte subset is generated when naïve 
CD4+ T cells are exposed to TGF-β and IL-21, or when central memory CD4+ T cells 
encounter inflammatory cytokines IL-1β and IL-6 (Acosta-Rodriguez, Napolitani et al. 
2007; Manel, Unutmaz et al. 2008; Volpe, Servant et al. 2008; Yang, Anderson et al. 
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2008).  The Th17 lymphocyte subset normally functions to control extracellular 
pathogens, but Th17 cells can also play an important role in human and animal 
experimental autoimmunity (Bettelli, Oukka et al. 2007).  Transfer of islet-specific Th17 
cells to NOD mice resulted in diabetes induction, but only after the cells had converted to 
largely IFN-γ-producing cells (Bending, De La Pena et al. 2009; Martin-Orozco, Chung 
et al. 2009).  The inhibition of Th17 cells, either with neutralizing anti–IL-17 antibodies 
or with recombinant IL-25, was shown to influence the course of diabetes development in 
NOD mice (Emamaullee, Davis et al. 2009).  Monocytes isolated from the blood of T1D 
patients were found to spontaneously secrete the proinflammatory cytokines IL-1β and 
IL-6, which are now known to induce and expand Th17 cell populations (Bradshaw, 
Raddassi et al. 2009).  However, Th17 cells do not in general seem to be independently 
responsible for the development of autoimmunity.  The Th1 cell subset can induce 
diabetes in the absence of Th17 cells. However, Th17 cells are not sufficient to induce 
disease in the absence of Th1 cells (Chitnis, Najafian et al. 2001; Bettelli, Sullivan et al. 
2004).  Recently, it was discovered that Th17 cells also generate large amounts of IL-9, a 
cytokine normally associated with immuno-suppressive functions produced by Th2 cells 
(Elyaman, Bradshaw et al. 2009).  To further add to the confusion, IL-17 was shown to 
have a protective effect in T-cell mediated intestinal inflammation (O'Connor, Kamanaka 
et al. 2009). 
The Tc17 lymphocyte subset can also produce IL-17 and usually releases IFN-γ as 
well (Kondo, Takata et al. 2009).   The Tc17 cell phenotype normally functions in the 
clearance of viral infection (Hamada, Garcia-Hernandez Mde et al. 2009). However Tc17 
cells can become diabetogenic if exposed to the inflammatory cytokine IL-23 (Ciric, El-
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behi et al. 2009). Little else is known at present about this recently described 
inflammatory T lymphocyte subset. 
 
Interleukin-10 
Interleukin-10, (IL-10) is an anti-inflammatory cytokine with a homodimeric 
subunit length of 160 amino acids and described immunosuppressive properties (Moore, 
Vieira et al. 1990; Yoon, Logsdon et al. 2006). IL-10 was identified in APCs including 
dendritic cell subsets (de Waal Malefyt, Abrams et al. 1991; Sica, Saccani et al. 2000). 
Mouse knockout studies showed that IL-10 can down-regulate autoimmunity in the 
intestine and is active in suppression of Crohn’s disease (Grimbaldeston, Nakae et al. 
2007; Minderhoud, Samsom et al. 2007). Autocrine production of IL-10 by immature 
DCs (iDCs), was shown to inhibit synthesis and release of pro-inflammatory cytokines 
and other molecules (IL-12, TNF-α, IL-6, LTB4, NO, PGE2), and to suppress Th1 
lymphocyte activity by down-regulating costimulatory molecule expression on the APC 
surface (Grutz 2005; Harizi and Gualde 2006). Through inhibition of these endogenous 
pro-inflammatory mediators, IL-10 is central to maintenance of DCs in an immature state 
and in the down-regulation of DC mediated inflammatory responses (Harizi and Gualde 
2006). In paracrine fashion, IL-10 synthesized by DCs regulates immunity by altering the 
function of different adjacent cell types. In two studies, IL-10 secreted by iDCs 
stimulated the development of cognate naïve Th0 cells into Th2 lymphocytes, or 
suppressor regulatory CD4+ T cells (Romagnani 1998; Romagnani, Kapsenberg et al. 
1998; Stassen, Fondel et al. 2004; Stassen, Schmitt et al. 2004). Since IL-10 can partially 
suppress T1D (Slavin, Maron et al. 2001) in combination with adjuvanted autoantigens 
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IL-10 may function in an additive or synergistic fashion to enhance multi-subunit 
vaccines for more effective immune suppression of T1D.  
 
Diabetes - autoantigen Therapy 
Immunologic tolerance induced by islet β-cell autoantigens was shown to 
partially suppress diabetes autoimmunity (Zhang, Davidson et al. 1991) and has been 
used since then in the treatment of the pathological inflammation associated with organ-
specific autoimmune diseases, particularly T1D.  This application was developed because 
the mechanisms of action of the autoantigen may be similar to those operating in the 
maintenance of immunological homeostasis (Vigouroux, Yvon et al. 2004). Prevention of 
autoimmune T1D onset or retardation of its progression by repeated oral inoculation with 
small amounts of pancreatic islet autoantigens has been demonstrated in animal models 
of autoimmune diabetes (Czerkinsky, Anjuere et al. 1999). Immunotherapy using major 
β-cell antigens such as insulin, GAD, or heat shock protein (hsp60), was shown in a 
variety of studies to delay or prevent T1D onset (Elliott, Qin et al. 1994; Tisch and 
McDevitt 1996; Atkinson and Leiter 1999). Oral inoculation with small amounts of islet 
autoantigens was shown to induce self-tolerance through IL-4 and Stat 6 activation of 
CD4+ Th2 and Th3 regulatory T cells that down-modulate autoreactive effector T cell 
inflammation at close proximity e.g., “bystander suppression”, (Hommann, Schotte et al. 
2001; Weiner 2001). Protection against T1D was shown to be associated with Th3 
regulatory lymphocyte secretion of TGF-β in prediabetic NOD mice gavaged with 
insulin, (Zhang, Davidson et al. 1991). Further, oral autoantigen inoculation generated 
partial diabetes suppression in patients (Chaillous, Lefevre et al. 2000; Millington, 
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Mowat et al. 2004). In several related Th1 cell mediated autoimmune diseases, collagen-
induced arthritis (Thompson and Staines 1986) and encephalomyelitis (Higgins and 
Weiner 1988), disease suppression was observed following prolonged feeding of small 
amounts of specific autoantigens. The induction of multiple sclerosis in animals was not 
only halted but reversed by feeding small amounts of myelin basic protein (MBP) 
suggesting that this type of oral autoantigen therapy can suppress and even aid in 
recovery from autoimmunity (Bitar and Whitacre 1988). 
Incidentally, most individual autoimmune diabetes vaccination strategies were 
developed in two mammalian (rodent) models that spontaneously develop T1D, the NOD 
mouse and the BioBreeding (BB) rat. These animal models have allowed detailed 
exploration of the altered communication between DCs of the innate arm of the immune 
system that underlies development of pancreatic β-cell-reactive effector T cells of the 
adaptive portion of the immune system. However, the animal model that has emerged as 
the most frequently employed for pre-clinical evaluation of prophylactic and therapeutic 
strategies for treatment of T1D has been the NOD mouse, which has an etiology of 
autoimmune diabetes similar to that of humans such as the influence of sex on disease 
incidence (Anderson and Bluestone 2005). 
 Preference for the NOD mouse model is based on a better defined genome, more 
monoclonal reagents for the analysis of immune system components and lower animal 
maintenance costs. So much preference has been placed on the NOD mouse for diabetes 
studies that other animal models frequently remain untested and potential differences in 
the NOD model as compared with humans are often neglected prior to extrapolations 
made to patients. More than 125 individual therapeutic strategies have been reported to 
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have a therapeutic effect on diabetes prevention in the NOD mouse (Atkinson and Leiter 
1999). However, most of these therapies have shown only partial suppression of the 
disease.  
In contrast to diabetes prevention, amelioration of diabetes hyperglycemia 
following disease onset is even more difficult to achieve. Less than a dozen 
immunomodulatory protocols have been reported to have a detectable therapeutic effect 
(Anderson and Bluestone 2005). Importantly, several of these therapies subsequently 
showed partial efficacy in clinical trials (Raz, Elias et al. 2001; Herold, Hagopian et al. 
2002; Keymeulen, Vandemeulebroucke et al. 2005). Based on the partial success in 
prevention of T1D onset in NOD mice, this mammalian model has often been considered 
to be an indicator of the potential for individual therapies in humans. 
 
Cholera Toxin B Subunit (CTB) Enhances Autoantigen-Mediated 
Immune Tolerance 
Cholera enterotoxin (CT) is an oligomeric protein produced in nature by the Gram-
negative bacterium Vibrio cholerae. The toxin causes excretion of a high volume of 
dilute (“rice water”) diarrhea initiated in the upper part of the small intestine. SDS-PAGE 
analysis showed that CT consists of a single large A subunit (CTA) of approximately 27 
kDa and a pentameric B subunit (CTB) with an approximate monomer molecular weight 
(MW) of 10.6 kDa (Lonnroth and Holmgren 1973). The CTA subunit can be subdivided 
into CTA1 and CTA2 subunits linked by a disulfide bond. The CTA1 subunit was found to 
be responsible for CT toxicity (Sattler and Wiegandt 1975). The assembly of CT structures 
revealed that the toxic CTA1 subunit contained ADP-ribosylating activity, while the 
helical CTA2 fragment was found to be responsible for embedding the CTA1 subunit 
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into the center of the doughnut shaped CTB pentameric oligomer (Sixma, Kalk et al. 
1993). In addition, the CTB subunit, held together by hydrogen bonds and salt bridges 
was shown to bind to ganglioside GM1[Gal(β1-3)galNac(β1-4)(NeuA-c(α2-
3)Gal(β14)Glc]ceramide (Merritt, Sarfaty et al. 1995) an anchor molecule embedded in 
the mammalian epidermal cell membrane (Holmgren, Lonnroth et al. 1973; Holmgren, 
Lonnroth et al. 1975) (Fig.  1.4).  Cholera toxin was shown to bind and infect a variety of 
somatic cells in vivo, especially intestinal epithelial cells, through high affinity binding of 
the toxin to its cell surface receptor GM1 ganglioside (Holmgren, Lindholm et al. 1974; 
Holmgren, Lonnroth et al. 1975; van Heyningen 1976; van Heyningen and King 1976). 
However, only epidermal cells in the Go/G1 phase of the cell cycle were shown to both 
bind and internalize CT. 
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Figure 1.4. Crystal structure of cholera toxin.  
The heterodimeric CTA protein subunit (blue) is composed of two polypeptide chains, 
CTA1 (22 kDa) and CTA2 (5 kDa), linked by a single disulfide bond. The enzymatically 
active CTA1 peptide is the (toxic) mono-ADP-ribosyltransferase subunit while the CTA2 
helical peptide links the CTA1 subunit to the pentameric CTB subunits. The cholera toxin 
B subunit (10.6 kDa) is composed of five identical polypeptide subunit chains (yellow, 
purple, red, orange and turquoise), each with membrane receptor GM1ganglioside 
binding capacity. 
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CT binds preferentially and almost exclusively to GM1 ganglioside (Sixma, 
Kalk et al. 1993; Sanchez and Holmgren 2008). Cholera toxin secretion in bacteria 
involves transport across the outer membrane through a CT secretion system known 
as the extracellular protein secretion system (Eps) (Camberg, Johnson et al. 2007). 
The energy for secretion is provided by EpsE, a cytoplasmic ATPase, that forms a 
complex with other secretory proteins to transfer CT across the periplasmic 
compartment (Camberg and Sandkvist 2005). This transfer is believed to be 
facilitated by the outer membrane component of the Eps, EpsD, which induces 
opening of the channel and subsequent secretion (Davis, Lawson et al. 2000). This 
protein transfer system moves CT from the periplasm where its subunits are 
assembled, across the membrane and into the extracellular environment (Hirst, 
Sanchez et al. 1984; Hardy, Holmgren et al. 1988). In order to mediate its toxic 
activity, CT binds with high affinity to GM1 ganglioside in lipid rafts on the 
epidermal cell surface of the lumen of the small intestine. The high binding affinity 
of CTB to ganglioside GM1 is due to the contribution of a single amino acid 
(Gly33) on the neighboring CTB monomer to the GM1 binding site on an adjacent 
CTB monomer (Merritt, Sarfaty et al. 1994). Subsequently, the crystal structure of 
CT revealed that Tyr12 on the CTB monomer along with Gly33 and Trp88 on the 
adjacent monomer are critical for CT-GM1 interaction (Jobling and Holmes 2002). 
The binding of CT via its CTB subunits to GM1 permits toxin endocytosis 
through caveolin-coated and clathrin-coated vesicles (Chinnapen, Chinnapen et al. 2007). 
In addition, CT was shown to enter cells through both Arf6 dependent and non-Arf6 
dependent pathways, which still remain unidentified (Chinnapen, Chinnapen et al. 2007). 
33 
Interestingly, blocking all known endocytic pathways does not appear to alter the 
toxicity of CT within the cell (Massol, Larsen et al. 2004). The toxin is transported not 
only to endosomes but also to the endoplasmic reticulum (ER) via Golgi retrograde 
transport mechanisms (Sandvig and van Deurs 2002). An endoplasmic reticulum 
retention motif (KDEL) is located near the C terminus of the CTA chain. This motif 
allows the toxin to interact with the KDEL receptor which permits recycling of ER 
components from the trans-Golgi network (TGN), back to the ER (Spooner, Smith et al. 
2006). Endocytosis of the toxin results in CTA1 subunit induction of adenylate cyclase. 
The up-regulation of adenylate cyclase activity occurs through CTA stimulation of ADP 
ribosylation of the adenylate cyclase Gsα subunit (O'Neal, Jobling et al. 2005). Increased 
intracellular cAMP concentrations result in an imbalance in electrolyte influx into the cell 
due to decreased sodium uptake by enterocytes and an increase in anion efflux from the 
cells. The decrease in sodium intake in addition to the extrusion of anions and 
bicarbonates causes water to be excreted from the cell into the lumen of the intestine. 
Ultimately, large amounts of water and electrolytes are lost from the intestinal epithelium 
resulting in severe bouts of “rice water” diarrhea. In addition, there is fluid loss from the 
intestine of up to 2 liters per hour leading to dehydration and death, usually by stroke in 
patients in which rehydration therapy is unavailable.  
 
The Cholera Toxin B subunit (CTB) Functions as a Carrier and 
Vaccine Adjuvant 
Enhanced immunogenic and adjuvant properties of microbial holotoxin B 
subunits such as CTB and heat-labile enterotoxin (LTB) from E. coli have been widely 
reported upon in a number of recent studies (Sun, Holmgren et al. 1994; Czerkinsky, Sun 
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et al. 1996; Guidry, Cardenas et al. 1997; Porgador, Staats et al. 1998; Sun, Xiao et al. 
2000; Eriksson and Holmgren 2002). The intact CT holotoxin was also found to be a 
potent mucosal immunogen. The presence of potent CT toxic effects, CT resistance to 
proteases and bile salts, as well as the high affinity of CT binding to ganglioside GM1 
and corresponding enzymatic ADP-ribosylating activity may contribute individually or 
together to establish the powerful immunostimulatory activity of CT (Sanchez and 
Holmgren 2008). Despite its strong immunogenic activity, and its wide use in animal 
vaccination protocols, the ability of CT to induce persistent inflammation has delayed 
application of the holotoxin as an adjuvant for stimulating immune responses in human 
vaccines.  
Despite this present drawback, oral CTB cholera vaccines have proved to be 
effective against cholera toxin (Arakawa, Yu et al. 1998; Lucas, Deen et al. 2005). 
Surprisingly, in addition to its known capacity to induce a pro-inflammatory response, 
oral administration of CTB subunit coupled with an autoantigen was shown to induce a 
state of immunological tolerance (George-Chandy, Eriksson et al. 2001; D'Ambrosio, 
Colucci et al. 2008). In early studies, oral delivery of CTB conjugated to specific 
autoantigens was shown to enhance autoantigen mediated protection of mice against 
several autoimmune diseases including autoimmune encephalomyelitis (Sun, Xiao et al. 
2000), autoimmune chondritis (Kim, Cheng et al. 2001), and uveitis (Phipps, Stanford et 
al. 2003). Further, CTB-autoantigen conjugates were shown to substantially suppress 
T1D in NOD mice (Bergerot, Ploix et al. 1997; Arakawa, Yu et al. 1998). Results of 
diabetes studies indicated that CTB-autoantigen conjugates reduced IFN-γ production 
and the migration of Tr1 regulatory T cells into pancreatic islets (Roncarolo, Levings et 
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al. 2001; Aspord and Thivolet 2002). Linkage of CTB to an autoantigen was shown to 
provide up to a 10,000-fold reduction in the amount of autoantigen required for 
generating immuno-tolerance (Arakawa, Chong et al. 1998; George-Chandy, Eriksson et 
al. 2001).  
Mechanisms underlying CTB-autoantigen modulated tolerance were shown to 
include inhibition of DC maturation, autoreactive T cell development and/or stimulation 
of Th2 and Foxp3 regulatory T cell proliferation and activation (Marinaro, Staats et al. 
1995; Lavelle, McNeela et al. 2003; Lavelle, Jarnicki et al. 2004). In other studies, 
Incubation of immature DCs with CTB was shown to induce DC maturation in 
experimental tumor models (George-Chandy, Eriksson et al. 2001; Isomura, Yasuda et al. 
2005). Morphological changes in DCs incubated with CTB included cell enlargement, 
elongation of DC dendrites and increased migration of DCs into draining lymph nodes as 
well as increased expression of the B7-2/CD86 co-stimulatory molecule (Isomura, 
Yasuda et al. 2005). Further, the mucosal administration of CTB conjugated to 
autoantigens was shown to mediate synthesis of T cell cytokines in response to the 
antigen or autoantigen complex. In experimental allergic encephalitis studies, the 
secretion of proinflammatory cytokines IL-12, IFN-γ, and TNF-α were significantly 
reduced while T cell expression of TGF-β was increased in animals treated with CTB 
conjugated to MBP (Sun, Xiao et al. 2000). Similarly, immunosuppressive cytokine 
secretion including increased IL-10 secretion was observed after oral administration of 
CTB conjugated to insulin, resulting in suppression of diabetes onset in NOD mice 
(Bergerot, Ploix et al. 1997; Ploix, Bergerot et al. 1999; Aspord and Thivolet 2002) 
(Fig.1.5). Based on the recent findings that inflammatory Th17 lymphocytes were 
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implicated in autoimmune disease pathogenesis, conjugation of CTB to myelin 
oligodendrocyte glycoprotein (MOG) delivered together with Complete Freund’s 
Adjuvant (CFA) resulted in suppression of lymphocyte IL-17 secretion (Sun and 
Holmgren unpublished results).  
 
CTB May Stimulate Tolerance through Binding DC Toll-like 
Receptors 
To maintain immunological homeostasis, DCs recognize pathogen antigens and 
autoantigens in the periphery. Immunological recognition is achieved by binding 
conserved PAMPS, to trans-membrane TLR domains (Takeda and Akira 2001; Takeda, 
Kaisho et al. 2003; Wen, Peng et al. 2004). Different PAMPS stimulate specific TLRs 
activating DC signal transduction pathways through adaptor proteins (e.g., MyD88), 
which lead to synthesis or stimulation of transcriptional activators e.g., NFkB, MAPKs, 
JNK and IRF3 as mentioned earlier. These transcriptional activators initiate expression of 
genes encoding specific cytokines (IL-12, IL-10), costimulatory molecules and 
chemokines that enable antigen activated DCs to guide the development of naïve Th0 cell 
into immunoreactive Th1 cells, Th2 immunosuppressive effector cells or regulatory T 
cell subsets (Kaisho and Akira 2001; Kaisho and Akira 2002).While most TLR agonists 
are potent adjuvants that promote the development of inflammatory Th1 effector cells, a 
number of reports show TLR2 ligands drive induction of Th2 lymphocyte populations 
that stimulate immunosuppression (Hemmi, Takeuchi et al. 2000; Kapsenberg 2003; 
Wen, Peng et al. 2004; Jarnicki, Conroy et al. 2008; Agrawal S 2003). Downstream 
transcriptional activator and adaptor proteins NFκB, AP-1 MyD88, Trif and pIRAK, 
were also significantly upregulated suggesting DC activation is involved in immune 
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suppression of T1D. In parallel studies, the E. coli enterotoxin B subunit (LTB, which is 
approximately 80% homologous in amino acid sequence to CTB), was shown to 
stimulate TLR2, resulting in regulatory T cell proliferation, IL-10 secretion and induction 
of Th2 anti-inflammatory lymphocyte development (Hajishengallis, Tapping et al. 2005; 
Sutmuller, den Brok et al. 2006; Sutmuller, Morgan et al. 2006).The structural 
homologies between CTB and LTB proteins and their amino acid sequences suggest 
similarities in mechanisms underlying inhibition of DC maturation (Marinaro, Staats et 
al. 1995; Lavelle, McNeela et al. 2003; Lavelle, Jarnicki et al. 2004). 
 
Conclusion 
 The cellular and molecular mechanisms responsible for adjuvant enhanced 
autoantigen mediated suppression of autoimmune responses remain largely obscure. The 
fusion of CTB subunits with autoantigens that in general stimulate immune tolerance 
against the linked autoantigen was found to exert a particularly useful effect in the 
prevention of organ-specific autoimmune disease onset (Arakawa, Yu et al. 1998; 
Arakawa, Yu et al. 1999; Kobayashi, Abiru et al. 2007). However, in several studies, 
fusion of the toxin B subunit to specific autoantigens such as carcinoembryonic antigen 
(CEA) or prostate specific antigen (PSA) resulted in stimulation of an inflammatory 
rather than an immunosuppressive response (Facciabene, Aurisicchio et al. 2007; 
Fensterle, Bergmann et al. 2008).  
 To understand how multi-component vaccines can function to prevent diabetes 
onset, it will be important to improve our understanding of mechanisms underlying T1D 
onset. One of the first steps required to reach this goal, will involve identification of 
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vaccine interactions with cells of the innate immune system involved in initial vaccine 
processing i.e., DCs.  It will be necessary to determine how DC processing of adjuvant-
autoantigen fusion proteins results in the initiation of immuno-reactive or immuno-
suppressive T cell populations capable of inhibiting the development of autoimmune T 
cell responses. 
 The experimental studies presented in this dissertation emphasize the focus of our 
laboratory in elucidation of early mechanisms underlying specific DC immune responses 
to inoculation with CTB subunit-diabetes autoantigen fusion proteins. The experimental 
results help to identify the role of protein adjuvants such as CTB linked to diabetes 
autoantigens on DC maturation and how these immunomodulated DCs influence the 
morphogenesis and proliferation of immunostimulatory Th1 and immunosuppressive Th2 
and/or regulatory T cell subsets to enhance the immunological suppression of diabetes 
onset ex vivo in humans. Mechanisms underlying multi-component vaccine stimulation of 
immunological tolerance must be more completely elucidated in order to fully harness 
this promising combinatorial vaccination strategy for transfer into safe and effective 
clinical therapy in T1D patients.   
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Figure 1.5. Adjuvant-autoantigen suppression of type 1 diabetes pathogenesis 
In this cartoon model, immature dendritic cells (iDC) in the gut periphery take up CTB-
INS/GAD fusion proteins from the intestinal lumen.  Alternatively, microfold (M)-cells 
overlaying the Peyer’s patches take up the fusion proteins by endocytosis, where they are 
then delivered to antigen presenting cells, particularly dendritic cells and macrophages 
that reside in the lamina propria.  Autoantigens, made more immunoreactive by linkage 
to the CTB adjuvant, modulate iDC processing and maturation favoring DC secretion of 
IL-10 and suppression of IL-12 secretion.  The anti-inflammatory cytokine IL-10 directs 
cognate Th0 cell development into immunosuppressive Th2 or iTreg (Th3 or Tr1) cell 
phenotypes.  CTB-INS/GAD may also activate CD4+CD25+ native regulatory T cell 
(nTreg) synthesis of transcriptional activator protein FOXP3, leading to further immune 
suppression activity. 
Figure adapted from: 
Afzali B. et al. (2007), Iwasaki A. and Kelsall, B.L. (2000), and a 2008 NIH R01 
application submitted by W. Langridge and I. Fodor to the National Institute of Digestive 
and Diseases of the Kidney (NIDDK) entitled, Immunostimulation of Autoantigen 
Mediated Tolerance. 
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Abstract 
Antigen presenting cells (APC); specifically dendritic cells (DCs) are a focal 
point in the delicate balance between T cell tolerance and immune responses contributing 
to the onset of type I diabetes (T1D). Weak adjuvant proteins like the cholera toxin B 
subunit when linked to autoantigens may sufficiently alter the balance of this initial 
immune response to suppress the development of autoimmunity. To assess adjuvant 
enhancement of autoantigen mediated immune suppression of T1D, we examined the 
cholera toxin B subunit (CTB)-proinsulin fusion protein (CTB-INS) activation of 
immature dendritic cells (iDC) at the earliest detectable stage of the human immune 
response. In this study, incubation of human umbilical cord blood monocyte-derived 
immature DCs with CTB-INS autoantigen fusion protein increased the surface membrane 
expression of DC toll-like receptor (TLR-2) while no significant upregulation in TLR-4 
expression was detected. Inoculation of iDCs with CTB stimulated the biosynthesis of 
both CD86 and CD83 co-stimulatory factors demonstrating an immunostimulatory role 
for CTB in both DC activation and maturation.  In contrast, incubation of iDCs with 
proinsulin partially suppressed CD86 co-stimulatory factor mediated DC activation, 
while incubation of iDCs with CTB-INS fusion protein completely suppressed iDC 
biosynthesis of both CD86 and CD83 costimulatory factors.  The incubation of iDCs with 
increasing amounts of insulin (INS) did not increase the level of immune suppression but 
rather activated DC maturation by stimulating increased biosynthesis of both CD86 and 
CD83 costimulatory factors. Inoculation of iDCs with CTB-INS fusion protein 
dramatically increased secretion of the immunosuppressive cytokine IL-10 and 
suppressed synthesis of the pro-inflammatory cytokine IL12/23 p40 subunit protein 
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suggesting that linkage of CTB to INS may play an important role in mediating DC 
guidance of cognate naïve Th0 cell development into immunosuppressive T lymphocytes.  
Taken together, the experimental data suggests that TLR-2 plays a dominant role in CTB 
mediated INS inhibition of DC induced T1D onset in humans.  Further, fusion of CTB to 
the autoantigen was found to be essential for enhancement of immune suppression as co-
delivery of CTB and INS did not significantly inhibit DC costimulatory factor 
biosynthesis. The experimental data presented supports the hypotheses that adjuvant 
enhancement of autoantigen mediated suppression of islet beta cell inflammation is 
dependent on CTB stimulation of DC TLR-2 receptor activation and co-processing of 
both CTB and the autoantigen in the same DC.     
 
Introduction 
Insulin dependent diabetes mellitus, or Type 1 diabetes (T1D), is the most 
destructive metabolic disease of children. T1D is caused by autoreactive lymphocyte 
destruction of insulin-producing islet β-cells of the pancreas (Eisenbarth 1986; Tisch and 
McDevitt 1996). The progressive loss of islet β-cell function results in an increasing 
deficiency of insulin production resulting in elevated blood sugar levels (hyperglycemia). 
The inability to transfer glucose from the blood into the cells of the body results in 
increased levels of cellular oxidative stress which leads to chronic inflammation 
throughout the body resulting in an increased and premature risk for secondary neural 
and circulatory health problems, including amputation of extremities, blindness, heart 
attack and stroke (Libby, Nathan et al. 2005). Young T1D patients must inject insulin 
several times a day for the rest of their lives or risk diabetic shock and death (Lodinova-
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Zadnikova, Prokesova et al. 2004).  
The first step in diabetes-mediated breakdown of immunological homeostasis 
leading to islet β-cell mortality is initiated by autoantigen-stimulated maturation of 
antigen-presenting cells (APCs), largely dendritic cells (DC).  Maturation of DCs induces 
the development of autoreactive CD8+ cytotoxic T cells (CTL) and CD4+ T helper (Th1) 
cells, as well as B cell production of autoantigen specific antibodies (Atkinson and 
Maclaren 1994; Tisch and McDevitt 1996; Han, Serra et al. 2005; Tang, Adams et al. 
2006).  Following autoreactive CD4+ Th1 cell infiltration of pancreatic islets in non-
obese diabetic (NOD) mice, autoreactive Th1 lymphocytes were shown to secrete the 
inflammatory cytokines IFN-gamma and IL-2.  These diabetes autoantibodies are known 
to stimulate macrophage and CTL secretion of oxidative compounds (NO, O2, H202) in 
addition to inflammatory cytokines (IL-1 beta, TNF-alpha, TNF-beta, IFN-gamma) 
(Atkinson and Maclaren 1994; Han, Li et al. 2005; Tang, Adams et al. 2006). The 
persistence of these immune responses induces chronic pancreatic inflammation 
(insulitis), which results in the induction of apoptosis of approximately 90% of the islet 
insulin-producing β-cells leading to insufficient levels of insulin production (Piccinni, 
Beloni et al. 1998).  A variety of immune cell types including B cells, dendritic cells 
(DCs), macrophages and natural killer (NK) cells were shown to be involved in the onset 
of diabetes pathogenesis (Kent, Chen et al. 2005; Wang, Zhang et al. 2005; Yoon and Jun 
2005; Cardell 2006; Silveira and Grey 2006; Tian, Zekzer et al. 2006; Tian, Hao et al. 
2009).  Specifically, DCs were shown to play a primary role in antigen priming of naïve 
Th cells (Th0) and in the modulation of their development into autoreactive Th1 
lymphocytes or immunosuppressive Th2 cells critical for maintenance of immunological 
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homeostasis (Pulendran, Smith et al. 1999; Pulendran, Kumar et al. 2001; Itano, 
McSorley et al. 2003). Immuno-cytochemical analyses showed that oral inoculation 
results in autoantigen uptake through M cells of the intestinal epithelium into peripheral 
DCs via several routes that may aid in the establishment of immune suppression (Yoon 
and Jun 2005). Autoantigens ( autoantigen (autoAg)) are taken up and processed by 
immature DC subsets (Figdor, de Vries et al. 2004). Following DC activation by 
autoantigens, the DCs migrate to adjacent lymph nodes, where they present antigen 
peptides on major histocompatibility complex class II (MHCII) receptors, synthesize co-
stimulatory molecules and secrete IL-12 which guides the development of naïve cognate 
Th0 cells into Ag-specific inflammatory Th1 lymphocytes.  In contrast, oral inoculation 
with small amounts of autoantigen was shown to induce DC production of the anti-
inflammatory cytokine IL-10 which stimulates the development of naïve Th0 
lymphocytes into anti-inflammatory Th2 lymphocytes, or alternatively into IL-10 or 
TGF-beta producing CD4+CD25+ Tr1 or Th3 regulatory T cells (Kapsenberg 2003; 
D'Ambrosio, Colucci et al. 2008). Thus, interactions between autoantigens, DCs and T 
cells in the gut-associated lymphoid tissues, may dictate the onset of inflammatory or 
tolerogenic outcomes following initial autoantigen (autoAg) presentation.  In addition, 
DCs residing in lymphoid follicles and the Peyer’s patches, shown to synthesize IL-10, 
were found to down-regulate Th1 cell mediated autoimmunity (Steinbrink, Wolfl et al. 
1997).  Further, immature or peripheral DCs (iDCs), that displayed low levels of co-
stimulatory molecule expression and that secreted cytokine IL-10, were shown to remain 
in the periphery and were found to induce Th2 lymphocyte mediated immunological 
tolerance (Rissoan, Soumelis et al. 1999; Liu, MacKenzie-Graham et al. 2001; Holmgren, 
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Adamsson et al. 2005; Li, Zhong et al. 2006). In an alternative set of experiments, the 
addition of IL-12 to iDCs induced autoreactive Th1 cell morphogenesis and accelerated 
T1D in NOD mice (Trembleau, Germann et al. 1995).  In composite, the available 
experimental data suggests that initial stages of T1D progression may be largely under 
DC control and may set the stage for anti-inflammatory or inflammatory disease 
outcomes (Shinomiya, Fazle Akbar et al. 1999).  
Oral administration of autoantigens has shown promise for prevention of 
spontaneous autoimmune diabetes (Zhang, Davidson et al. 1991; Trentham, Dynesius-
Trentham et al. 1993). However, the need for repeated autoantigen administration over an 
extended period of time poses a limitation to such therapy.  Further, a low efficiency of 
immune suppression was reported in previously sensitized hosts (Arakawa, Yu et al. 
1998). These limitations were largely overcome through application of the nontoxic B 
subunit of the cholera enterotoxin (CTB) from Vibrio cholerae. The CTB molecule was 
shown to be a strong immunomodulator for induction of oral tolerance when used as a 
carrier molecule for conjugated autoantigens (Sun, Holmgren et al. 1994; Sun, Rask et al. 
1996; Sun, Li et al. 2000; Sun, Xiao et al. 2000).  The bacterial AB enterotoxin from 
Vibrio cholerae, cholera toxin (CTX) contains a toxic ADP-ribosyltransferase subunit A1 
(CTA1), linked through a small helical (A2) peptide to a pentamer of non-toxic B carrier 
subunits (CTB). The CTB subunits were shown to be required for binding the toxin to 
monosialoganglioside receptor molecules embedded in gut epithelial cell membranes 
facilitating entry of the holotoxin into the cell (Eriksson and Holmgren 2002). The CTB 
subunit was shown to bind specifically to GM1-ganglioside, a receptor molecule found in 
common on the membrane of most types of epidermal cells. Thus, CTB can provide an 
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efficient trans-mucosal carrier molecule for autoantigen induction of peripheral tolerance 
(Sun, Holmgren et al. 1994; Shreedhar, Kelsall et al. 2003).   
In previous studies, oral delivery of CTB conjugated to specific autoantigens was 
shown to enhance autoantigen mediated protection of mice against several organ-specific 
autoimmune diseases including autoimmune encephalomyelitis (Sun, Xiao et al. 2000) 
autoimmune chondritis (Kim, Cheng et al. 2001) and uveitis (Phipps, Stanford et al. 
2003). In addition, CTB-INS conjugates were shown to substantially suppress diabetes in 
NOD mice (Bergerot, Ploix et al. 1997; Arakawa, Yu et al. 1998).  The observed 
suppression of diabetes onset was associated with a reduction in Th1 cell IFN-γ 
production and the migration of Tr1 regulatory T cells into pancreatic islets (Roncarolo, 
Levings et al. 2001; Aspord and Thivolet 2002). Further, the fusion of CTB to insulin 
was shown to provide up to a 10,000-fold reduction in autoantigen amounts required for 
immuno-tolerization (Arakawa, Chong et al. 1998; George-Chandy, Eriksson et al. 2001). 
Mechanisms underlying CTB modulated immune suppression of T1D may include the 
inhibition of DC maturation, inhibition of autoreactive T cell development and/or 
induction of Th2 and inducible T regulatory cell (iTreg) proliferation and activation 
(Marinaro, Staats et al. 1995; Lavelle, McNeela et al. 2003; Lavelle, Jarnicki et al. 2004).   
Recent immunotherapy and vaccination strategies strongly target receptors that 
mediate immune cell activation. Pathogen recognition receptors, especially TLRs 
expressed by APCs, have received increasing attention because activation of innate 
immunity through pathogen protein, nucleic acid and lipopolysaccharide (LPS) pattern 
recognition has been increasingly identified as an essential first line of immunological 
defense (Hemmi, Takeuchi et al. 2000; Schnare, Barton et al. 2001; Takeda, Kaisho et al. 
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2003).  In general, TLRs interact with a variety of microbial structures widely expressed 
by fungi, bacteria, protozoa and viruses conferring a relatively high degree of specificity 
to the immune response (Takeda, Kaisho et al. 2003). Recent developments support the 
concept that activation of immunity by microbial molecules may involve cooperative 
interaction with multiple host receptors within the membrane lipid raft (Triantafilou, 
Miyake et al. 2002; Beutler, Jiang et al. 2006; Hoebe, Jiang et al. 2006). That is, TLRs 
are usually present as preformed homodimers with the exception of TLR2, which 
preferentially forms heterodimers with either TLR1 or TLR6 (Akira and Takeda 2004).  
Toll like receptors TLR2/TLR1 and TLR2/TLR6 were shown to be activated in response 
to agonists such as lipoteichoic acid and lipoproteins, while other APC surface and 
internal TLRs respond to a variety of bacterial and virus DNA and LPS 
immunostimulatory molecules (Akira and Hemmi 2003; Takeda, Kaisho et al. 2003; 
Roger, Miconnet et al. 2005; Kanzler, Barrat et al. 2007). Recently, the type II heat-labile 
enterotoxin from E. coli which has an AB5 subunit structure similar to cholera toxin was 
found to stimulate cytokine release in mouse and human cells through interactions with 
TLR2. However, up to the present, the mechanism of CTB mediated TLR activation is 
only poorly understood. An increased understanding of the initial interactions between 
CTB and its fusion proteins with TLRs is predicted to improve our understanding of 
mechanisms by which these molecules exert their immunomodulatory activities.  
The objectives of this study are to clarify mechanisms underlying early events in 
CTB-INS vaccine induction of immunological tolerance leading to the suppression of 
T1D through analysis of CTB-proinsulin autoantigen induced inhibition of human 
immature DC activation and maturation leading to induction of Th0 lymphocyte 
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development into inflammatory Th cells resulting in chronic pancreatic islet 
inflammation and the death of insulin producing islet β-cells. Examination of CTB and 
CTB-INS fusion protein interactions with DC membrane TLRs will provide information 
on whether they or other membrane receptors may play a role in the initiation of 
adjuvant-autoantigen mediated DC activation and maturation. Through analysis of CTB-
autoantigen fusion protein interactions with immature DCs we may be able to gain a 
clearer understanding of how CTB-INS fusion proteins interact with DCs to suppress the 
onset of T1D. 
 
Materials and Methods 
Construction of Bacterial Plasmids Containing CTB-INS 
A gene encoding approximately 258bp of human proinsulin (INS) was physically 
linked to the carboxyl-terminus (309bp) of CTB to generate the fusion gene CTB-INS. 
The cholera toxin B subunit–autoantigen fusion gene CTB-INS was cloned into the (A) 
configuration of the E. coli expression vector pRSET (Invitrogen™, Carlsbad, CA), 
under control of the bacteriophage T7 promoter in order to achieve high levels of 
transgene expression. The pRSET vector also contained an oligonucleotide encoding 6 
histidines immediately upstream of the CTB permitting isolation of the transgene 
product. The CTB-INS fusion gene (567bp) was cloned between the BamH1/Bgl1 and 
EcoR1 sites flanked by a termination sequence and a poly (A) adenylation sequence in 
the 3’ region of the transgene. Selective clones were assessed by DNA sequence analysis 
to confirm the in-frame linkage of CTB and Insulin DNA fragments (Fig. 2.1A). The 
expression vector pRSET-CTB-INS containing the gene encoding the CTB-INS fusion 
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protein was introduced into E. coli producer strain BL21 (DE3)pLysS (Invitrogen, 
Carlsbad, CA) for nickel affinity column isolation of the recombinant protein (Carter, Yu 
et al. 2006).  
 
Synthesis and Isolation of CTB-INS Fusion Proteins 
The CTB-INS transformed E. coli strain BL-21, was grown in 250 ml Luria Broth 
(LB) medium containing ampicillin (100mg/ml). While still in log phase of growth, CTB-
INS protein synthesis was stimulated by addition of 90 mg isopropyl β-D-1thiogalacto-
pyranoside (IPTG), (Sigma Chemical Co. St. Louis, MO), to the bacterial culture. After 6 
hr continued growth at 370C, the bacterial culture was transferred into 50 ml polystyrene 
Oakridge tubes and the cells harvested by centrifugation in a SA-600 rotor for 10 min, at 
5,000 rpm and 40C, in a Sorvall RC5B centrifuge. The cell pellet was resuspended in 1.0 
ml/tube of 10 mM HEPES buffer (pH 7.5), containing 100 mM imidazole. The cells were 
disrupted by sonication at 3 x 10 sec bursts at 10 W, with a Sonic 60 Dismembrator, 
(Fisher Scientific, and Sunnyvale, CA).  The CTB-INS protein was isolated and purified 
from the bacterial homogenate using a Maxwell Model 16 robotic protein purification 
system (Promega Inc.TM), according to the protein isolation protocol provided by the 
manufacturer (Promega Inc., Madison, WI). In order to obtain a pure protein product, the 
robot employs electromagnetically charged Magne-His Nickel-Iron alloy particles with 
an affinity for the 6-HIS tag linked to the N terminus of the recombinant CTB-INS fusion 
protein. Imidazole was removed from the protein mixture by dialysis of the preparation 
against 2 x 1.0 Liter, 10 mM HEPES buffer (pH 7.5), for 4 hr at 40C. The purity of the 
isolated CTB-INS protein (23.4kDa) was determined by electrophoretic mobility analysis 
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in a 12% polyacrylamide gel in comparison with protein molecular weight standards 
(Fig. 2.1B).  The purified CTB-INS protein was stored at -200C until further use.     
 
Isolation and Culture of Monocyte-Derived DC from Human Cord 
Blood 
Monocyte-derived dendritic cells (MDDC) were prepared from freshly collected 
human umbilical cord blood (Appendix 1). The leukocyte fraction of approximately 50 ml 
of cord blood obtained from normal healthy placenta donors (by LLU IRB approved 
protocols), was separated from red blood cell and platelet fractions by Ficoll-paque density 
gradient centrifugation for 30 min at 2,000 rpm @ 4oC, in a Beckman Coulter Allegra X-
15R centrifuge equipped with an SX4750 rotor (Appendix 2). The CD14+ monocytes were 
obtained from the total lymphocyte fraction by incubation with anti-CD14 PE 
(Phycoerythrin) for 10 min @ 4oC followed by incubation with anti-PE magnetic 
microbeads for 15 min at 4oC. The cells were separated magnetically by passing them 
through the MACS column as described by the manufacturer (Miltenyi Biotech, Auburn, 
CA) (Devaraj, Glaser et al. 2006; Devaraj, Dasu et al. 2008).  The purity of the monocyte 
fraction was determined by flow cytometry in a BD FACSCalibur flow cytometer (BD 
Biosciences, San Jose, CA. 
The isolated monocytes were cultured in 6 cm non-pyrogenic polystyrene culture 
plates in RPMI 1640 culture medium (Mediatech Inc. Manassas, VA, USA) in a humidified 
atmosphere of 5% CO2 at 37 °C (Preprotech, Rocky Hill, NJ) (Appendix 4). The medium 
was supplemented with 10% fetal bovine serum (FBS), 1 mM glutamine, 100 U/ml 
penicillin, 100 μg/ml streptomycin, 50 ng/ml human recombinant GMCSF, and 10 ng/ml 
human recombinant IL-4 (ProSpec-Tany TechnoGene, Rehovot Science Park, Israel).  The 
monocyte cell culture was fed every 2 days by gentle replacement of 50% of the medium  
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Figure 2.1 Construction of the CTB-INS Fusion Gene and Isolation of the Gene Product. 
Panel A shows the plasmid map of the E. coli expression vector pRSET A (Invitrogen™, 
Carlsbad, CA), carrying the CTB-INS fusion gene. The cholera toxin B subunit–
proinsulin autoantigen gene fusion, CTB-INS (567bp), was cloned into pRSET (A) 
between the BamH1/Bgl 1 and EcoR1 sites. The expression vector pRSET-CTB-INS 
with the CTB-INS coding sequence under control of the bacteriophage T7 promoter also 
contains an oligonucleotide region encoding 6 histidine amino acid residues immediately 
5’ upstream of the CTB DNA sequence. The recombinant plasmid was introduced into 
the E. coli recipient strain BL21 (DE3) pLysS, for CTB-INS fusion protein expression 
and for nickel binding isolation of the recombinant protein using a Maxwell 16 TM protein 
isolation robot (Promega Inc, Madison, WI, USA). Panel B is an SDS polyacrylamide gel 
stained with Commasie blue, Lane 1: Molecular Weight Marker Proteins (BIO-RAD, 
Hercules, CA); Lane 2: pRSET-CTB protein (16.1kDa); Lane 3: the CTB-INS fusion 
protein isolated and purified from BL21 E. coli cells containing pRSET-CTB-INS 
(23.4kDa). 
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with fresh medium. The cell cultures were kept in their original plates until harvested to 
avoid induction of DC maturation caused by mechanical stress associated with replating the 
cells. The percentage of monocyte-derived immature dendritic cells (M-iDC) was 
determined directly by flow cytometry based on expression of DC specific cell surface 
markers (CD14−HLA-DR+CD11c+) after 6 days further incubation. 
 
DC Maturation Assay and Phenotyping 
The iDCs were stimulated by the addition of CTB (10ug/ml), insulin (10ug/ml), CTB-
INS fusion protein (20ug/ml) and Phorbol myristate acetate (PMA) and Ionomycin at 
10ng/ml (PMA+Ionomycin) for 48 hrs at 37oC in 5% CO2.  After incubation, the 
expression of DC surface markers indicating their state of activation and maturation 
(CD14, CD11c, and HLA-DR) was determined by flow cytometry. Briefly, the gated 
CD14- HLA-DR+ CD11c+ cell population was analyzed for the expression of CD86, and 
CD83 activation markers (BD Pharmingen, San Jose, CA USA). 
 
Flow Cytometry Analysis 
For flow cytometry examination of DC surface markers, the DCs were surface stained 
with antibodies conjugated to Phycoerythrin (PE), Fluorescein isothiocyanate (FITC), 
Allophycocyanin (APC), and Peridinin Chlorophyll Protein Complex (PerCP) (Parrish, 
Baez et al. 2009) and resuspended in 1.0% of freshly prepared formaldehyde for analysis 
using the FACSCalibur flow cytometer. The following antibodies were used to identify 
the different cell subsets:  anti-CD86-FITC, anti-CD83-PE, anti- HLA-DR PerCP anti-
CD14-APC anti-mouse IgG1 FITC, anti-mouse IgG1 PE, anti-mouse IgG1 HLA-DR, 
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anti-mouse IgG1 APC (BD Pharmingen); 7-Amino-actinomycin D (7-AAD) was used to 
assess viability of the collected cells. Briefly, a pooled sample of harvested cells was 
incubated with 7-Amino-actinomycin D (7-AAD) and prepared for flow cytometry 
according to the manufacturer’s instructions (eBioscience, San Diego, CA, USA). 
Fluorescence intensity on all flow histograms is shown on a log scale. Forward scatter 
(FSC) and Side Scatter (SSC) and percentage of cell population on histograms are shown 
in a linear scale. 
 
Secreted Cytokine Analysis by Cytometric Bead Array 
 Immature DCs were stimulated with PMA+Ionomycin and proteins for 48 hrs as 
described above. The supernatant was collected and stored at -20oC until analyzed for 
concentrations of IL-10 and IL-12 using the cytometric Bead Array (CBA) kit (Becton 
Dickinson Biosciences, San Jose, CA, USA).  Briefly, 50 µl of premixed beads coated 
with capture antibodies was incubated with 50µl of cytokine standards or test samples in 
the dark at room temperature for 1 hr. Following the incubation, 50µl of a mixture of PE-
conjugated antibodies prepared against the specific cytokines was added to each 
preparation, and the samples incubated for 2 hrs in the dark at room temperature. The 
beads were washed once with the wash buffer supplied with the CBA kit and analyzed 
immediately in a BD FACSCalibur flow cytometer (Becton, Dickinson Inc.). Data 
analysis was performed using the FCAP Array software packages supplied by BD 
Biosciences. Three thousand counting events were acquired from each sample. Cytokine 
calibration curves were generated using cytokine standards supplied by BD Biosciences 
(Potapova, Gaudette et al. 2007; LaFrance, Kehinde et al. 2008).    
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Results 
CTB-INS Mediated Suppression of DC Maturation involves 
Upregulation of TLR2 
To determine whether TLR2 or TLR4 was involved in CTB-INS mediated DC activation, 
flow cytometric analysis of TLR2 and TLR4 markers was carried out on vaccine 
inoculated activated DCs.  The results of flow cytometry analysis indicated that CTB and 
CTB-INS inoculated DCs significantly upregulated the presence of TLR2 proteins on the 
surface of the vaccine inoculated DC membrane in comparison with unstimulated DCs, 
insulin treated DCs and PMA+Ionomycin treated DCs (p<0.05) (Fig. 2.2). No significant 
up-regulation of TLR4 receptor protein was detected on the surface of CTB, CTB-INS 
and insulin treated DCs. However, TLR4 was significantly upregulated in 
PMA+Ionomycin treated cells compared to CTB and CTB-INS treated cells (p<0.05), a 
result consistent with those obtained earlier by Thierry et al. (2005) (Roger, Miconnet et 
al. 2005). The finding that TLR2 is upregulated by CTB-INS treated cells and not on 
insulin treated cells suggests that CTB-INS mediated suppression of DC maturation, 
similar to that found for the E. coli heat sensitive enterotoxin B subunit is attributable to 
CTB activation of iDCs through induction of TLR2 rather than TLR4. 
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Figure 2.2: TLR2 upregulation by CTB-INS. The bar graph represents the percentages of 
dendritic cells expressing Toll-like receptors 2 and 4 (TLR2 and TLR4). Umbilical cord 
blood monocyte derived immature DC were stimulated for 48 hrs with CTB, CTB-INS, 
Insulin and PMA+Ionomycin and the induction of TLR2(CD282) and TLR4(CD284) was 
determined by flow cytometric TLR-specific antibody surface staining methods. The 
mean and standard error of the mean (SE) were calculated for three separate experiments 
(p<0.05). 
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CTB-INS Treatment Suppresses Maturation of Dendritic Cells 
The influence of CTB, Insulin, CTB-INS and PMA+Ionomycin on immature DC 
iDC) activation and maturation was examined by measuring the expression of DC 
synthesized co-stimulatory molecules CD86 and CD83.  iDC were differentiated from 
monocytes as described in methods and materials section and assessed for the expression 
of CD14-HLA-DR+CD11C+ surface markers indicating DC differentiation from 
monocytes (Fig. 2.3A). The iDC (CD14-HLA-DR+CD11C+) were inoculated with CTB, 
INS and CTB-INS fusion proteins and assessed for stimulation of DC membrane surface 
marker expression, indicating activation and maturation, i.e., CD86 and CD83, 
respectively (Fig. 2.3B).  Flow cytometric data obtained for CTB-INS treated cells 
revealed that iDC exposure to CTB-INS resulted in a significant level of suppression of 
CD86 and CD83 costimulatory factors as compared with CTB, INS, and 
PMA+Ionomycin (p<0.05). These results suggest that the physical linkage of CTB to the 
Insulin autoantigen is responsible for suppression of DC activation and maturation by 
CTB-INS.    
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Figure 2.3 Dendritic Cell Activation and Maturation is Suppressed by CTB-INS Fusion 
Protein. Panel A: Flow cytometry dot plot showing dendritic cells differentiated from 
monocytes isolated by ficoll gradient centrifugation from human umbilical cord blood. 
The CD14+ monocytes were supplemented with granulocyte macrophage colony 
stimulating factor (GM-CSF) and IL-4 and were cultured for 6 days to obtain CD14-
HLA-DR+CD11c+ immature human DCs. To determine the viability of DCs isolated 
from the entire population of collected cells (Upper left panel), 7-AAD negative cells 
were gated (Upper right panel) and analyzed for expression of the surface marker CD14 
(Lower left panel). The CD14- cells were gated and analyzed for co-expression of HLA-
DR and CD11c differentiation markers by flow cytometry (Lower right panel). Panel B:  
The histograms depict the expression of CD83 and CD86 after stimulation of DCs for 48 
hrs with CTB, CTB-INS, Insulin and PMA+Ionomycin. Maturation state of the DCs was 
determined by flow cytometric analysis. The data are representative of three independent 
experiments with comparable results.  
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Linkage of CTB to Autoantigen is Necessary for Suppression of DC 
Activation 
 Based on the results obtained from the insulin stimulation studies described 
above, it was important to examine the role of CTB in the observed suppression of DC 
activation.  Therefore immature DCs were stimulated with 10ug insulin alone, co-
delivered with 10ug CTB and finally stimulated with equivalent amounts of CTB-INS 
fusion protein.  Co-delivery of insulin + CTB resulted in significant CD83 and CD86 co-
stimulatory factor upregulation on DC compared to unstimulated DCs (p<0.05). 
However, cells treated with CTB-INS fusion proteins showed almost no CD83 and CD86 
upregulation as measured by mean fluorescent intensity analysis for each treatment group 
(Fig. 2.4A).  Samples treated with CTB, CTB-INS and PMA+Ionomycin showed a 
significant increase in cell populations expressing CD86 and CD83 in comparison with 
the control (unstimulated) DC sample (p<0.05). Interestingly, the population of cells 
expressing CD83 was significantly reduced in comparison with the population of cells 
expressing the CD86 costimulatory factor (p<0.05). However the ratios of costimulatory 
expression for each treatment group remained unchanged (data not shown). Taken 
together, the data indicate that the physical linkage of CTB to the autoantigen is essential 
for achieving high levels of immunological suppression of DC activation. 
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Figure 2.4: Effects of CTB on Insulin Mediated DC Activation  
Immature monocyte derived DCs were stimulated for 48 hrs with 10ug insulin + 10ug 
CTB, 20ug CTB-INS and PMA+Ionomycin as a positive control for DC activation. The 
activation and maturation of DCs measured by expression of CD86 and CD83 cell 
surface markers was determined by flow cytometric methods. The mean fluorescence 
intensity (MFI) and percentage population data is representative of four repeated 
independent experiments with comparable results. Panel A: The overlapping histograms 
depict the expression of CD83 and CD86 costimulatory factors in immature dendritic 
cells after stimulation with PMA+Ionomycin, Insulin + CTB and CTB-INS.  The 
statistical significance for difference in MFI between treatment groups was calculated 
based on p<0.05. 
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Increased Amounts of Insulin Induce Dendritic Cell Activation 
 The effect of increasing concentrations of insulin protein on DC activation was 
investigated by stimulating iDCs with increasing amounts of insulin from 10ug/ml up to 
250ug/ml. There was no significant difference in the upregulation of CD86 co-
stimulatory molecules on the DC cell surface for concentration 10ug/ml up to 50ug 
insulin/ml. However, mean fluorescence intensity measurements suggest a progressive 
increase in the expression of CD86, when the concentration of insulin was increased to 
100ug/ml and 250ug/ml respectively (Fig. 2.5A). We also observed an increase in the 
percentage of the DC cell population activated by increasing the amount of insulin 
P<0.05 (Fig. 2.5B).  Based on the increasing levels of CD86 fluorescence intensity 
detected, increases in the percentage of activated DCs were shown to correlate with 
increasing amounts of insulin. Our experimental data did not reveal a significantly 
different level of CD83 protein synthesized in cells incubated with 100ug/ml and 
250ug/ml insulin.  Predictably, PMA+Ionomycin induced significantly increased levels 
of DC synthesis of CD86 and CD83 costimulatory factors compared to other treatment 
groups (p<0.05).  
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Figure 2.5: Increasing Insulin Dosage Results in DC Activation. Immature monocyte 
derived DCs were stimulated for 48 hours with different amounts of insulin and 
PMA+Ionomycin.  Activation of DCs was determined by flow cytometric methods. The 
data presented are representative of more than three independent experiments with 
comparable results. Panel A: Graph indicating increasing mean fluorescence intensity of 
CD86 expression on DC cell surfaces with increasing amounts of insulin. Panel B: 
Histogram showing the percentages of cells activated by different concentrations of 
insulin as measured by CD86 costimulatory factor expression on the DC cell surface. 
*p<0.05 for statistical differences between treatment groups. 
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CTB-INS Stimulates Increased Synthesis of IL-10 
 To determine whether CTB-INS suppression of DC maturation (suppression of 
co-stimulatory factor synthesis), resulted in increased secretion of immunosuppressive 
cytokine IL-10 and decreased synthesis of IL-12, the supernatant medium was collected 
from DCs exposed to 48 hrs incubation with CTB-INS fusion protein and analyzed by 
cytometric bead assay (CBA) based flow cytometry for the presence of secreted 
cytokines.  The results of this experiment showed that there was a significant increase in 
IL-10 production by DCs incubated with CTB-INS compared to DCs stimulated with the  
autoantigen alone (p<0.05) with a concurrent decrease in proinflammatory cytokine IL-
12/23p40 oligomer compared to PMA+Ionomycin treated DCs (p<0.05).  Incubation of 
immature DCs with CTB-INS resulted in a 2.5-fold pg/ml increase in synthesis of IL-10 
in comparison with DC incubation with CTB, insulin or PMA+Ionomycin treated cells.  
Although CTB alone appeared to stimulate DC IL-10 synthesis, the cytokine levels were 
significantly lower than CTB-INS induced DC IL-10 production (p<0.05) (Fig. 2.6). In 
summary, CTB-INS induced suppression of DC activation and maturation appears to be 
followed by an increased secretion of the anti-inflammatory cytokine IL-10 and a 
decrease in secreted IL-12/23p40, suggesting the possibility of immune suppression of 
inflammatory cytokine synthesis. 
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Figure 2.6.  CTB-INS Fusion Protein Stimulates IL-10 Synthesis 
Panel A: The histograms show the mean fluorescence intensity of IL-10. Premixed plastic 
beads coated with capture antibodies (BD Biosciences, San Jose, CA, USA) and a 
mixture of Phycoerythrin-conjugated antibodies against IL-10 were incubated for 2 hrs 
with the supernatant removed from different treatment conditions of proteins with DCs as 
described in the Materials and Methods section.  The beads were washed and analyzed by 
flow cytometry for determination of the fluorescence intensity of bound IL-10. Panel B: 
Cytometric Bead Array-defined concentrations of IL-10 and IL-12/23p40 subunit 
measured from cell supernatants taken from DCs receiving different treatment conditions. 
For each treatment the concentration of IL-10 and IL-12/23p40 subunit was normalized 
to standard IL-10 and IL-12/23p40 cytokine curve and given in pg/ml. The data are the 
Mean and SE (*P<0.05) showing statistically significant differences between CTB-INS 
treated cells and PMA + Ionomycin treated cells for repeated independent experiments. 
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Discussion  
  Our laboratory and others previously demonstrated the phenomenon of 
suppression of insulitis and autoimmune diabetes in NOD mice inoculated with CTB-INS 
(Bergerot, Ploix et al. 1997; Arakawa, Yu et al. 1998; Sobel, Yankelevich et al. 1998).  
However, the cellular and molecular mechanisms underlying CTB-proinsulin – immune 
cell interactions involved in the suppression of disease pathology are incompletely 
understood.  Because DCs are the dominant population of APCs involved in the induction 
of inflammatory and autoreactive T cell morphogenesis, we investigated early effects of 
CTB-INS on human iDC activation and maturation in vitro and attempted to correlate 
these results with findings from NOD mice diabetes onset studies. 
 Our experiments suggest that CTB when conjugated to pro-insulin (CTB-INS) 
results in the suppression of DC activation and maturation as determined by a failure of 
CTB-INS and to a limited extent proinsulin alone to stimulate the upregulation of CD86 
and CD83 costimulatory factors on iDC.  This observation was further confirmed when 
CTB-INS stimulated DCs resulted in an increase in DC secretion of the anti-
inflammatory cytokine IL-10.  Further, our experimental data appears to confirm 
previous studies with the heat sensitive enterotoxin from E. coli (LTB), that CTB, a 
molecule similar in structure to LTB like LTB selectively stimulates TLR2 activation in 
response to DC incubation with CTB or CTB-INS proteins. Previous observations show 
that CTB can greatly enhance the immunogenicity of linked antigens (George-Chandy, 
Eriksson et al. 2001; D'Ambrosio, Colucci et al. 2008) by inducing DC upregulation of 
CD86 and CD83 (George-Chandy, Eriksson et al. 2001; Isomura, Yasuda et al. 2005). 
Morphological changes which included enlargement of iDC, elongation of DC dendrites 
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and increased migration of DCs into draining lymph nodes observed in those studies was 
not monitored in the present study. D’Ambrosio et al. suggested that CTB could partially 
prevent LPS-induced maturation of monocyte-derived DCs while Morita et al. reported 
that CTB induced DC maturation. Careful consideration of these findings appears to 
suggest that CTB may play a dual role as both an immunostimulatory and 
immunosuppressive modulator molecule. We report that CTB activation of DCs appears 
to be less than PMA+Ionomycin induced activation of DC maturation. However, when 
compared to insulin and CTB-INS, CTB shows a significantly increased level of DC 
activation. In essence, the question of the duality of CTB activity either as a pro-
inflammatory or anti-inflammatory immune response modulator may be resolved by 
understanding the activity of CTB in relation to another molecule (antigen or 
autoantigen).  
Earlier NOD mouse insulin inoculation experiments conducted by Bergerot et al., 
demonstrated sustained prevention of diabetes onset, even when oral insulin treatment 
was initiated as late as 15 weeks after birth of the mice. In addition, the protective effect 
against continued insulitis development was transferable to untreated NOD mice through 
transfer of CD4+ T cells from CTB-INS inoculated animals (Bergerot, Ploix et al. 1997). 
Our recent finding that CTB-INS is active in the suppression of DC maturation provides a 
possible explanation for CTB enhanced insulin-mediated diabetes suppression observed 
in NOD mice studies employing CTB-INS fusion protein produced in viruses, plants, and 
silkworm larvae (Denes, Krausova et al. 2005; Gong, Jin et al. 2007; Gong, Long et al. 
2009).  
Previous studies demonstrated that insulin can function as a prime target for 
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autoantigen directed T1D therapies (Palmer, Asplin et al. 1983; Jaeckel, Klein et al. 
2003; Jaeckel, Lipes et al. 2004; Kent, Chen et al. 2005). These studies showed that 
administration of insulin analogs, such as altered B: 9-23 insulin, induced T cell 
mechanisms involved in the prevention of diabetes development in NOD mice (Weiner, 
Zhang et al. 1991; Zhang, Davidson et al. 1991; Elliott, Qin et al. 1994; Atkinson and 
Leiter 1999; Weiner 2001; Kobayashi, Abiru et al. 2007). However, a major concern is 
that increasing amounts of insulin can act as a double edged sword with the potential to 
protect against the development of autoimmunity at low insulin concentrations while 
stimulating pathogenic immunity at higher insulin concentrations (Romagnani 1998; 
Kobayashi, Abiru et al. 2007). Liu et al. (2009) recently demonstrated that increased 
insulin concentration (2.5-25mg/L) significantly increased DC synthesis of co-
stimulatory factors, increasing DC ability to activate autologous lymphocytes (Liu, Wang 
et al. 2009). Our experimental data showed that exposure of iDCs to increasing amounts 
of insulin resulted in an increase, rather than a further suppression, of DC activation. This 
result provides a plausible answer to the earlier counter intuitive observation that 
increased insulin levels might be expected to stimulate rather than suppresses diabetes 
onset in NOD mice.  
The observed increase in suppression of DC maturation by CTB-INS fusion 
protein in comparison with insulin alone raises the question of whether CTB-INS 
suppression of DC maturation is mediated through the activation of Toll-like receptor 
signaling processes.  The type II heat-labile enterotoxin (LT-IIB) of E. coli, which has an 
AB5 type structure similar to CTB, was shown to induce DC activation through TLR2 
resulting in downstream activation of NF-κB (Connell, Metzger et al. 1995; Lencer, 
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Constable et al. 1995; Merritt, Sarfaty et al. 1995; Hajishengallis, Tapping et al. 2005). 
Examination of CTB-mediated suppression of DC activation and maturation similarly 
suggests that TLR2 may be selectively upregulated as well in CTB stimulated DCs.  The 
CTB subunit may be selective for TLR2 since TLR2 depends specifically on hydrophobic 
interactions for ligand binding (Okusawa, Fujita et al. 2004; Seong and Matzinger 2004) 
as observed for LTBIIb. While the specific mechanism by which CTB may interact with 
TLR2 is largely inferred from LTB studies, further insights may be provided from the 
binding properties of CTB and other pentameric enterotoxin B subunits that have the 
capacity to participate in both hydrophobic and hydrophilic interactions (van den Akker, 
Sarfaty et al. 1996; Tinker, Erbe et al. 2003).  
DC activation correlates with expression of the major immunosuppressive 
cytokine, IL-10, identified in APCs including DC subsets (de Waal Malefyt, Abrams et 
al. 1991; Sica, Saccani et al. 2000). Autocrine production of IL-10 by iDCs was shown to 
inhibit synthesis and release of pro-inflammatory cytokines and other molecules (IL-12, 
TNF-α, IL-6, LTB4, NO, PGE2). Further, IL-10 secretion by DCs was shown to suppress 
Th1 lymphocyte activity by enhancing down-regulation of costimulatory molecule 
expression on the DC surface (Grutz 2005; Harizi and Gualde 2006). In the case of 
experimental encephalitis, oral administration of CTB linked to myelin basic protein 
(MBP) increased suppression of encephalitis induced by TGF-β originating from CD4 T 
cells in the animal spinal cord (Sun, Xiao et al. 2000). In the same way, immunological 
analyses of patients with Behcet’s disease treated with CTB conjugated to HSP60 p336-
351 in a pilot clinical trial showed the presence of increased synthesis of IL-10 by CD4+ 
cells as well as a reduction in T cell synthesis of pro-inflammatory cytokines IL-2 and 
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IFN-γ (Stanford, Whittall et al. 2004). Through inhibition of the above endogenous pro-
inflammatory mediators, IL-10 was shown to be central to maintenance of DCs in an 
immature state and in the down-regulation of DC-mediated inflammatory responses 
(Harizi and Gualde 2006). In paracrine fashion, IL-10 synthesized by DCs can regulate 
immunity by altering the function of different adjacent cell types. In several studies, IL-
10 secreted by iDCs stimulated the development of cognate naïve Th0 cells into either 
Th2 lymphocytes, or suppressor regulatory T cells (Romagnani 1998; Romagnani, 
Kapsenberg et al. 1998; Stassen, Fondel et al. 2004; Stassen, Schmitt et al. 2004). Studies 
in knockout mice showed that IL-10 can down-regulate autoimmunity in the intestine and 
can be active in the suppression of Crohn’s disease (Grimbaldeston, Nakae et al. 2007; 
Minderhoud, Samsom et al. 2007).  
In our experiments, CTB-INS stimulated iDCs produced significantly higher 
levels of IL-10 than in CTB or proinsulin stimulated iDCs. However of interest, the 
biosynthesis of IL-12/23p40 subunit was significantly inhibited. This result is critical 
because induction of cognate naïve T helper cell (Th0) morphogenesis into Th1 effector 
cells that secrete IFN-γ and IL-2 responsible for islet inflammation and β-cell death is 
dependent on DC synthesis of IL-12 in addition to expression of surface costimulatory 
molecules (Pulendran, Smith et al. 1999; Itano, McSorley et al. 2003; Kang and Kim 
2006; Zorena, Mysliwska et al. 2008). Secretion of IL-10 was shown to be essential for 
the inhibition of DC maturation through its effect of blocking IL-12 synthesis. As a result 
of increased DC biosynthesis of IL-10, inflammatory autoreactive effector Th1 cell 
proliferation and secretion of downstream inflammatory cytokines IFN-γ and IL-2 is 
inhibited. This finding in combination with our experiments demonstrating CTB-INS 
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inhibition of DC co-stimulatory factor upregulation and IL-12/23p40 synthesis may be 
critical to determine the probable cellular mechanisms underlying CTB-INS mediated 
immune suppression of T1D.  Future experiments incubating CTB linked autoantigens 
with naïve DCs will reveal the capacity of CTB-INS to arrest the progression of T1D 
once hyperglycemia has become established.  Establishment of CTB-INS mediated 
immunological suppression of T1D progression will help to determine whether this form 
of interventional therapy in combination with anti-inflammatory cytokines can prevent 
both the onset and the progression of diabetes once hyperglycemia has developed.  Once 
durable immunological suppression of diabetes progression has been achieved, 
interventional therapy with insulin producing mesenchymal stem cells may provide an 
effective, safe and durable cure for the present ravages of autoimmune diabetes.   
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Abstract 
Dendritic cells (DC), the largest population of antigen presenting cells, regulate 
the delicate balance between immune responses and tolerance involved in the onset of 
type I diabetes (T1D). Cholera toxin B subunit (CTB) is a known mucosal adjuvant for 
the generation of immune responses to linked antigens. However, CTB linked to 
autoantigens may induce tolerance and therefore suppress the induction of autoimmunity. 
In this present study, we examined the possibility that CTB linked to a 5 kDa C-terminal 
protein fragment of the diabetes autoantigen glutamic acid decarboxylase (GAD), may 
directly suppress the maturation of DCs assessed by CD86, CD83, CD80 and CD40 
biosynthesis. Furthermore, we examined the possibility that CTB-GAD35 may suppress 
human DC maturation and function in response to phorbol myristate acetate (PMA) and 
Ionomycin stimulation.  Incubation of human umbilical cord blood monocyte-derived 
DCs (iDCs) with GAD induced low level surface expression of CD86, CD83, CD80 and 
CD40 co-stimulatory factors compared to untreated samples, while incubation of iDCs 
with CTB-GAD35 did not induce expression of CD86, CD83, CD80 and CD40 co-
stimulatory factors. Also, our findings showed that CTB-GAD35 abrogates PMA and 
Ionomycin induced iDC maturation.  Further, suppression of iDC maturation by CTB-
GAD35 is accompanied by a dramatic decrease in the secretion of IL-12/23p40 and IL-6 
pro-inflammatory cytokines while increasing the secretion of the immunosuppressive 
cytokine IL-10.  These findings suggest that linkage of CTB adjuvant to the dominant 
T1D autoantigen GAD may play a critical role in stimulating DC priming of naïve Th0 
cell development into immunosuppressive T lymphocytes. This could be important in 
adjuvant stimulated vaccine responses for suppression of T1D autoimmunity. 
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Introduction 
TYPE 1 DIABETES MELLITUS (T1DM) is an organ-specific autoimmune 
disease which results from autoreactive lymphocyte destruction of insulin-producing 
pancreatic islet beta cells (Eisenbarth 1986; Tisch and McDevitt 1996). The loss of islet 
β-cell function leads to insulin deficiency and elevated blood sugar levels 
(hyperglycemia). Hyperglycemia increases levels of cellular oxidative stress leading to 
chronic inflammation throughout the body. Therefore, diabetics have an increased and 
premature risk for secondary neural and circulatory health problems, including blindness, 
heart attack, and stroke (Libby, Nathan et al. 2005). 
Dendritic cells (DCs), professional antigen presenting cells (APC), are implicated 
in mediating islet β-cell destruction in T1D. Through antigen presentation, DCs play a 
key role in the polarization and development of naïve T helper cells (Th0) into 
autoreactive Th1 lymphocytes or immunosuppressive Th2 cells. This process is critical 
for maintenance of immunological homeostasis (Pulendran, Smith et al. 1999; Pulendran, 
Kumar et al. 2001; Itano, McSorley et al. 2003). Maturation of DCs in response to “self” 
antigens such as pancreatic islet β-cell proteins induces the development of autoreactive 
CD8+ cytotoxic T lymphocytes (CTL) and CD4+ T helper (Th1) lymphocytes in addition 
to initiating B cell production of autoantibodies. Subsequently, autoreactive Th1 cells 
infiltrate the pancreatic islets in non-obese diabetic (NOD) mice while secreting 
inflammatory cytokines such as IFN-gamma and IL-2.  These cytokines are known to 
stimulate macrophage and CTL secretion of oxidative compounds NO, O2, H2O2 in 
addition to other inflammatory cytokines (IL-1 beta, TNF-alpha, TNF-beta) [5-7].  
Consequently, these immune responses induce chronic pancreatic inflammation 
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(insulitis), which results in apoptosis of the islet β-cells ultimately leading to insufficient 
levels of insulin production and availability (Piccinni, Beloni et al. 1998). 
In addition to induction of conventional Th1 and Th2 cells, DCs induce the 
development of adaptive regulatory T cells (iTregs) for the maintenance of immunologic 
tolerance (Kapsenberg 2003). Immuno-cytochemical analyses showed that M cells of the 
intestinal epithelium uptake autoantigens into peripheral DCs via several routes and this 
may aid in the establishment of immune tolerance (Yoon and Jun 2005).  Following 
activation, DCs migrate to adjacent lymph nodes. Here, they present antigen peptides on 
major histocompatibility complex class II (MHCII) receptors, synthesize costimulatory 
factors, and secrete cytokines. Together, these three signals guide the development of 
naïve cognate T cells into antigen-specific inflammatory Th1 lymphocytes or anti-
inflammatory Th2 lymphocytes. Immature or peripheral DCs (iDCs), that displayed high 
levels of costimulatory molecule expression and secreted cytokine IL-12, were found to 
induce Th1 lymphocyte differentiation; while those that displayed low levels of 
costimulatory molecule expression and secreted cytokine IL-10 induced the development 
of Th2 lymphocytes (Rissoan, Soumelis et al. 1999; Liu, MacKenzie-Graham et al. 2001; 
Holmgren, Adamsson et al. 2005; Li, Zhong et al. 2006).  
Oral delivery of autoantigens such as insulin and glutamic acid decarboxylase 
(GAD) resulted in partial suppression of diabetes symptoms in diabetic animals (Zhang, 
Davidson et al. 1991; Czerkinsky, Anjuere et al. 1999).  However, this form of anti-
inflammatory therapy requires repeated autoantigen administration over an extended 
period of time. Adjuvants were considered to enhance autoantigen therapy to further 
prevent T1DM onset (Weiner, Zhang et al. 1991; Zhang, Davidson et al. 1991). The 
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mucosal adjuvant, cholera enterotoxin B subunit (CTB) from Vibrio cholerae, was shown 
to be highly efficient for induction of oral tolerance in T1DM when conjugated with islet 
autoantigens (Sun, Holmgren et al. 1994; Sun, Rask et al. 1996; Sun, Li et al. 2000; Sun, 
Xiao et al. 2000). The CTB subunit was shown to bind specifically to GM1-ganglioside, 
a receptor molecule found in common on the membrane of most types of epidermal cells. 
This facilitates the entry of the holotoxin into the cell (Eriksson and Holmgren 2002). 
Thus, CTB is an efficient trans-mucosal carrier molecule for autoantigen induction of 
peripheral tolerance (Sun, Holmgren et al. 1994; Shreedhar, Kelsall et al. 2003). Our 
laboratory has compared the protective effects of diabetes-specific autoantigens, such as 
GAD and proinsulin (INS), when genetically conjugated to adjuvants such as heat labile 
enterotoxin-LTB from enterotoxigenic Escherichia coli, the enterotoxin B chain from 
Shigella-STB and the plant toxin ricin B subunit-RTB on diabetes onset in NOD mice. 
(Carter, Yu et al. 2006).   
Our laboratory has recently shown that a possible mechanism for the suppression 
of T1D onset is the induction of immune tolerance through DC interaction with CTB- 
autoantigen. The inoculation of human DCs with CTB-INS fusion protein resulted in an 
enhanced suppression of DC maturation. In addition, CTB-INS stimulated DCs increased 
their secretion of immunosuppressive cytokine IL-10 with a concurrent suppression of 
inflammatory cytokine IL-12/23p40 (Odumosu, Payne et al. 2010). We hypothesized that 
if the mechanism of immune suppression was similar that the fusion protein CTB-GAD35 
could also exert an inhibitory affect on DC maturation. Thus, through analysis of CTB-
GAD35 fusion protein interactions with iDCs, we anticipated that we might be able to gain 
a clearer understanding of the mechanisms underlying CTB-autoantigen fusion protein 
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interactions with DCs to suppress the onset of T1D. 
 
Materials and Methods 
Expression and Purification of CTB-GAD35 Fusion Proteins in E. coli 
A cDNA fragment encoding a 5-kDa peptide (amino acid 509-543) proximal to the 
carboxyl-terminus of GAD65 –designated GAD35 was genetically linked to the carboxyl-
terminus (309bp) of CTB to generate the fusion gene CTB-GAD35. The cholera toxin B 
subunit–autoantigen fusion gene CTB-GAD35 was cloned into the (A) configuration of 
the E. coli expression vector pRSET (Invitrogen™, Carlsbad, CA), under control of the 
bacteriophage T7 promoter in order to achieve high levels of transgene expression. The 
pRSET vector also contained an oligonucleotide encoding 6 histidines immediately 
upstream of the CTB permitting isolation of the transgene product. Selective clones were 
assessed by DNA sequence analysis to confirm the in-frame linkage of CTB and CTB-
GAD35 DNA fragments. Recombinant vectors were then introduced into E. coli producer 
strain BL21 (DE3)pLysS (Invitrogen, Carlsbad, CA) by electroporation for nickel affinity 
column isolation of the recombinant protein (Carter, Yu et al. 2006). 
Recombinant CTB-GAD35 fusion protein expressed in E. coli was purified by 
isolating the 6xHis-tagged protein from lysed cells using metal chelation 
chromatography. Transformed E. coli strain BL-21, was grown in 250 ml Luria Broth 
(LB) medium containing ampicillin (100mg/ml) with shaking at 37oC. While still in log 
phase of growth, CTB-GAD35 protein synthesis was stimulated by addition of 90 mg 
isopropyl β-D-1thiogalacto-pyranoside (IPTG), (Sigma Chemical Co. St. Louis, MO), to 
the bacterial culture. After 6 hr continued growth at 370C, the bacterial culture was 
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pelleted by centrifugation in a SA-600 rotor for 10 min, at 5,000 rpm and 4oC, in a 
Sorvall RC5B centrifuge. The cell pellet was resuspended in 1.0 ml/tube of 10 mM 
HEPES buffer (pH 7.5), containing 100 mM imidazole. The cells were disrupted by 
sonication at 3 x 10 sec bursts at 10 W, with a Sonic 60 Dismembrator (Fisher Sci. 
Sunnyvale, CA).  The CTB-GAD35 protein was isolated and purified from the bacterial 
homogenate using a Maxwell Model 16 robotic protein purification system (Promega Inc. 
TM), according to the protein isolation protocol provided by the manufacturer (Promega 
Inc., Madison, WI). In order to obtain a pure protein product, the robot employs 
electromagnetically charged Magne-His Nickel-Iron alloy particles with an affinity for 
the 6-HIS tag linked to the N terminus of the recombinant CTB-GAD35 fusion protein. 
Imidazole was removed from the protein mixture by dialysis of the preparation against 2 
x 1.0 Liter, 10 mM HEPES buffer (pH 7.5), for 4 hr at 4oC. The purity of the isolated 
CTB-GAD35 protein (~22kDa) was determined by electrophoretic mobility analysis in a 
12% polyacrylamide gel in comparison with protein molecular weight standards (Figure 
1b).  The purified CTB-GAD35 protein was confirmed by immunoblot analysis using an 
anti-polyhistidine primary antibody and stored at -20oC until further use. 
 
Isolation and Culture of Monocyte-derived DC from Human Cord 
Blood 
Monocyte-derived dendritic cells (MDDC) were prepared from freshly collected 
human umbilical cord blood. The leukocyte fraction of cord blood obtained from normal 
healthy placenta donors (by LLU IRB approved protocols) was separated from red blood 
cell and platelet fractions by Ficoll-paque (GE Healthcare, Uppsala, Sweden) density 
gradient centrifugation for 30 min at 2,000 rpm@ 4oC,  in a Beckman Coulter Allegra X-
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15R centrifuge, equipped with a SX4750 rotor. The CD14+ monocytes were obtained from 
the total lymphocyte fraction by incubation with anti-CD14 PE (Phycoerythrin) (Miltenyi 
Biotech, Auburn, CA) for 10 min @ 4oC followed by incubation with anti-PE magnetic 
microbeads for 15 min at 4oC. The cells were separated magnetically by passing them 
through the MACS column as described by the manufacturer (Miltenyi Biotech) (Devaraj, 
Glaser et al. 2006; Devaraj, Dasu et al. 2008).  The purity of the monocyte fraction was 
determined by flow cytometry in a BD FACSCalibur flow cytometer (BD Biosciences, San 
Jose, CA, USA). 
The isolated monocytes were cultured in 6 cm non-pyrogenic polystyrene culture 
plates in RPMI 1640 culture medium (Mediatech Inc. Manassas, VA, in a humidified 
atmosphere of 5% CO2 at 37 °C (Preprotech, Rocky Hill, NJ). The medium was 
supplemented with 10% fetal bovine serum (FBS), 1 mM glutamine, 100 U/ml penicillin, 
100 µg/ml streptomycin, 50 ng/ml human recombinant GM-CSF, and 10 ng/ml human 
recombinant IL-4 (ProSpec-Tany TechnoGene, Rehovot Science Park, Israel).  The 
monocyte cell culture was fed every 2 days by gentle replacement of 50% of the medium 
with fresh medium. The cell cultures were kept in their original plates until harvested to 
avoid induction of DC maturation caused by mechanical stress associated with replating the 
cells. The percentage of monocyte-derived iDC (M-iDC) was determined directly by flow 
cytometry based on expression of DC-specific cell surface markers (CD14−HLA-
DR+CD11c+) after 6 days further incubation. 
 
DC Maturation Assay and Phenotyping 
The iDCs were stimulated by the addition of CTB (10ug/ml), GAD35 (10ug/ml), CTB-
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GAD35 fusion protein (20ug/ml) and Phorbol myristate acetate (PMA) and Ionomycin at 
10ng/ml (PMA+Ionomycin) for 48 hrs at 37oC, in 5% CO2.  After incubation, the 
expression of DC surface markers, indicating their state of activation and maturation 
(CD14, CD11c, HLA-DR), was determined by flow cytometry. The gated CD14- HLA-
DR+ CD11c+ cell population was analyzed for the expression of CD86, CD83, CD80, and 
CD40 activation markers (BD Pharmingen, San Jose, CA USA). 
 
Flow Cytometry Analysis 
For flow cytometry examination of DC surface markers, the DCs were surface stained 
with antibodies conjugated to PE, Fluorescein isothiocyanate (FITC), Allophycocyanin 
(APC), and Peridinin Chlorophyll Protein Complex (PerCP) (Parrish, Baez et al. 2009) 
and resuspended in 1.0% of paraformaldehyde for analysis using the FACSCalibur flow 
cytometer. The following antibodies were used to identify the different cell subsets:  anti-
CD86-FITC, anti-CD83-PE, anti-CD40-FITC, anti-CD80-PE, anti-HLA-DR-PerCP anti-
CD14-APC anti-mouse IgG1-FITC, anti-mouse IgG1-PE, anti-mouse IgG1-HLA-DR, 
anti-mouse IgG1-APC (BD Pharmingen); 7-Amino-actinomycin D (7-AAD) was used to 
assess viability of the collected cells. Briefly, a pooled sample of harvested cells was 
incubated with 7-AAD and prepared for flow cytometry according to the manufacturer’s 
instructions (eBioscience, San Diego, CA, USA). Fluorescence intensity on all flow 
histograms is shown on a log scale.  
 
Secreted Cytokine Analysis by Cytometric Bead Array 
Immature DCs were stimulated with PMA+Ionomycin and proteins for 48 hrs as 
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described above. The supernatant was collected and stored at -20oC until analyzed for 
concentrations of IL-6, IL-10 and IL-12/23p40 using the cytometric Bead Array (CBA) 
kit (Becton Dickinson Biosciences, San Jose, CA). Fifty µl of premixed beads coated 
with capture antibodies was incubated with 50µl of cytokine standards or test samples in 
the dark at room temperature for 1 hr. Following the incubation, 50µl of a mixture of 
Phycoerythrin-conjugated antibodies prepared against the specific cytokines was added to 
each preparation, and the samples were incubated for 2 hrs in the dark at room 
temperature. The beads were washed once with the wash buffer supplied with the CBA 
kit and analyzed immediately in a BD FACSCalibur flow cytometer (Becton, Dickinson 
Inc.). Data analysis was performed using the FCAP Array software packages supplied by 
BD Biosciences. Three thousand counting events were acquired from each sample. 
Cytokine calibration curves were generated using cytokine standards supplied by BD 
Biosciences (Potapova, Gaudette et al. 2007; LaFrance, Kehinde et al. 2008). 
 
Statistical Analysis 
Statistical analyses of experimental treatment groups were performed using a one-way 
analysis of variance method (ANOVA).   Cell population percentages and fluorescence 
intensity values were presented as the mean ± 95% confidence interval.  A p< 0.05 was 
considered statistically significant. 
 
Results 
CTB-GAD35 Fusion Protein Expression in E.coli 
 Recombinant GAD35 and CTB-GAD35 were identified by immunoblot with a 
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monoclonal antibody made against the carboxyl terminal epitope of GAD65.  The CTB-
GAD35 protein was identified in both monomeric (~22kDa) and multimeric form (Fig. 
3.1A). In addition, identification of GAD35 and CTB-GAD35 was confirmed by 
immunoblot analysis using an anti-polyhistidine antibody.  
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3.1A. 
 
3.1B. 
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Figure 3.1.  A. Diagram of E. coli pRSET (A) expression vector.  
The cDNA fragment of cholera toxin B subunit (CTB) C-terminus was fused to the 5kDa 
pancreatic islet autoantigen glutamic acid decarboxylase (GAD). The vector includes a 
bacteriophage T7 promoter to generate high expression levels of inserted genes and a 6 
histidine sequence tag for nickel affinity column isolation of recombinant protein. (B) 
Immunoblot identification of renatured GAD35 and CTB-GAD35 subunit fusion proteins 
synthesized in E. coli.  Proteins identified with anti-His primary antibody. 
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CTB-GAD35 Suppresses Monocyte-derived Dendritic Cell Activation and Maturation 
We examined the influence of CTB, GAD35, CTB-GAD35 and lipopolysaccharide (LPS) 
on immature DC maturation by measuring the surface expression of costimulatory 
molecules CD86, CD83, CD80 and CD40.  Immature dendritic cells (iDC) were 
differentiated from monocytes and assessed for the expression of CD14-HLA-
DR+CD11c+ surface markers indicating DC differentiation from monocytes. iDCs 
(CD14-HLA-DR+CD11c+) were inoculated with CTB, GAD35 and CTB-GAD35 fusion 
proteins and assessed for surface expression of CD86, CD83, CD80 and CD40 ( Fig. 
3.2).  Flow cytometric data obtained for CTB-GAD35 treated cells revealed that iDC 
exposure to CTB-GAD35 resulted in a significantly lower expression of CD86, CD83, 
CD80 and CD40 costimulatory factors as compared with CTB, GAD35, and LPS 
(p<0.05). These results suggest that the physical linkage of CTB to the GAD35 
autoantigen is responsible for suppression of dendritic cell activation and maturation by 
CTB-GAD35. 
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Figure 3.2. CTB-GAD35 suppresses activation and maturation of DCs.  
Dendritic cells were stimulated for 24 hrs with CTB, GAD35, CTB-GAD35 and LPS. 
Markers of DC activation and maturation were determined using flow cytometry. 
Histograms depict the expression of CD86, CD83, CD80 and CD40 after stimulation. 
Shaded histogram represents untreated sample (negative control). 
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CTB-GAD35 Downregulates PMA and Ionomycin-induced DC 
Surface Costimulatory Molecule Expression 
 Based on the results obtained showing that CTB-GAD35 suppresses DC 
maturation, we further assessed the capacity of CTB-GAD35 to prevent activation of DCs 
in the presence of PMA+Ionomycin stimulation. Separate cultures of DCs were treated 
with PMA and Ionomycin alone and a combination of PMA+Ionomycin plus CTB-
GAD35.  In preliminary experiments, 24-hr and 48-hr treatments were tested. Results 
showed that the effects of CTB-GAD35 on PMA+Ionomycin DCs were more evident 
during the first 24 hrs (data not shown).  Therefore, in subsequent experiments, we used 
the 24-hr time points. As shown in Figure 3.3, CTB-GAD35 induces a statistically 
significant reduction of PMA+Ionomycin induced up- regulation of CD86, CD83 and 
CD80 (p<0.05). 
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Figure 3.3. CTB-GAD35 suppresses PMA+Ionomycin induced maturation of DCs. 
Dendritic cells were stimulated with PMA+Ionomycin and a combination of 
PMA+Ionomycin and CTB-GAD35 for 24 hrs. Maturation of DCs was determined using 
flow cytometry. Histograms depict the expression of CD86, CD83, CD80 DC 
costimulatory factors following fusion protein, PMA and Ionomycin stimulation. 
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CTB-GAD35 Suppresses DC Pro-inflammatory Cytokine Secretion 
 In these experiments, we determined whether CTB-GAD35 suppression of DC 
maturation (suppression of costimulatory factor surface expression) resulted in a 
decreased synthesis of IL-12/23p40 and IL-6, along with an increased secretion of 
immunosuppressive cytokine IL-10. The culture medium was collected from DCs 
exposed to 48 hrs incubation with CTB-GAD35 fusion protein and analyzed for the 
presence of secreted cytokines by cytometric bead array based flow cytometry.  The 
results of this experiment showed that there was a significant decrease in pro-
inflammatory cytokines IL-12/23p40 and IL-6 with a concomitant increase in IL-10 
production by DCs incubated with CTB-GAD35  compared to DCs stimulated with the  
autoantigen alone (P<0.05) (Fig. 3.4). Therefore, taken together, the observed down 
regulation of co-stimulatory surface marker expression, in addition to the significant 
decrease in secreted IL-12/23p40 and IL-6 inflammatory cytokines and increased 
secretion of the anti-inflammatory cytokine IL-10, CTB-GAD35 clearly appears to have 
an important role in the suppression DC activation and maturation. 
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Figure 3.4: The CTB-GAD35 fusion protein suppresses the secretion of proinflammatory 
cytokines IL-12/23p40 and IL-6 while increasing synthesis of the anti-inflammatory 
cytokine IL-10. Premixed plastic beads coated with capture antibodies (BD Biosciences, 
San Jose, CA, USA). And a mixture of Phycoerythrin-conjugated antibodies against IL-
12/23p40, IL-6 and IL-10 were incubated for 2 hr with media removed from DC cultures 
incubated with CTB and GAD autoantigen treatment conditions as described in the 
section on materials and methods. The beads were washed and analyzed by flow 
cytometry to determine the concentrations of IL-10, IL-6 and the IL-12/23p40 subunit. 
The cytokine concentrations in the samples were normalized to a standard IL-10, IL-6 
and IL-12/23p40 cytokine curve and concentrations were provided in pg/ml. The data 
represent the Mean and SE for cytokine concentration in pg/ml (*p < 0.05) of repeated 
independent CTB-GAD fusion treatment experiments in comparison with the 
uninoculated cell control sample, autoantigen alone and/or PMA+ Ionomycin treatment 
samples. 
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Discussion 
Using a CTB-insulin fusion protein, Bergerot et. al. demonstrated sustained 
prevention of diabetes onset in NOD mice as late as 15 weeks after birth. Further, a 
sustained protective effect against the development of insulitis was shown to be 
transferable to un-inoculated NOD mice through adoptive transfer of CD4+ T cells from 
CTB-INS inoculated animals (Bergerot, Ploix et al. 1997).  Additional experiments in our 
laboratory and by others have demonstrated that inoculation with CTB-autoantigen fusion 
proteins suppresses insulitis and autoimmune diabetes in NOD mice (Bergerot, Ploix et 
al. 1997; Arakawa, Yu et al. 1998; Sobel, Yankelevich et al. 1998).   Specifically, our 
animal immunization studies revealed that CTB-GAD35 inoculated animals showed 
reduced levels of hyperglycemia and pancreatic islet inflammation as compared to 
controls (Denes, Krausova et al. 2005; Denes, Yu et al. 2006). In a separate in vivo study, 
our laboratory recently demonstrated that a combinatorial therapy of CTB-GAD35 + IL-10 
is able to completely suppress the onset of diabetes in NOD mice (Denes, Fodor et al. 
2010).  However, molecular and cellular mechanisms underlying tri-component vaccine 
suppression of T1D remain to be elucidated.  The dominant role of DCs in the induction 
of inflammation and tolerance implicates them in an early stage of the mechanism 
involved in CTB-GAD35 suppression of diabetes onset.   
DC synthesis of IL-12 and expression of surface costimulatory molecules are 
responsible for induction of T cell morphogenesis into pro-inflammatory autoreactive 
Th1 effector cells that secrete inflammatory cytokines IFN-γ and IL-2.  This T cell 
response is responsible to a large extent for the onset and development of insulitis and β-
cell death in T1D (Pulendran, Smith et al. 1999; Itano, McSorley et al. 2003; Kang and 
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Kim 2006; Zorena, Mysliwska et al. 2008). Conversely, production of IL-10 by iDCs was 
shown to suppress biosynthesis and secretion of pro-inflammatory cytokines and other 
molecules (IL-12, TNF-α, IL-6, LTB4, NO, PGE2).  Synthesis of IL-10 was also shown 
to be essential for the inhibition of DC maturation by suppressing IL-12 synthesis. As a 
result of increased DC IL-10 production, autoreactive Th1 cell proliferation and secretion 
of downstream inflammatory cytokines IFN-γ and IL-2 is inhibited. Here we report that 
the adjuvant – autoantigen fusion protein CTB-GAD35 stimulated iDCs to synthesize 
significantly higher levels of IL-10 than was observed for iDCs stimulated with CTB or 
PMA+Ionomycin. 
Th17 cells have become very important for the treatment of autoimmune diseases 
because they have been identified as significant effector cell types involved in both 
human and mouse autoimmune models (Fujino, Andoh et al. 2003; Nakae, Nambu et al. 
2003; Komiyama, Nakae et al. 2006). IL-17 was first detected in the serum and tissues of 
patients with autoimmune diseases such as multiple sclerosis (MS), systemic lupus 
erythematous (SLE) and rheumatoid arthritis (RA) (Wong, Ho et al. 2000; Tzartos, Friese 
et al. 2008). In addition, IL-17 blockade was shown to prevent the development of EAE 
while IL-17 knockout mice showed resistance to the development of EAE and collagen-
induced arthritis (CIA) (Nakae, Nambu et al. 2003; Hofstetter, Ibrahim et al. 2005).  
Together, these findings suggest that the regulation of Th17 differentiation and function 
may prove to be a potential treatment for autoimmune diseases. IL-6 has been found to be 
an effective target for down-regulating the differentiation of Th17 cells as a treatment for 
autoimmune diseases (Nishimoto, Terao et al. 2008; Yokota, Imagawa et al. 2008). This 
inflammatory cytokine has evolved as a pleiotropic cytokine involved in regulating the 
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balance of IL-17 producing Th17 cells and Treg cells (Bettelli, Carrier et al. 2006; 
Mangan, Harrington et al. 2006).  In this study, our findings show that CTB-GAD35 
suppresses DC synthesis of IL-6. This result in combination with CTB-GAD35 inhibiting 
DC co-stimulatory factor up-regulation may be critical elements in the elucidation of 
cellular mechanisms responsible for CTB-GAD35 mediated immune suppression of T1D.  
The efficacy of diabetes autoantigens as a vaccine for suppression of 
autoimmunity appears to be increased when physically conjugated to an adjuvant. The 
conjugation of CTB to antigens was shown to significantly enhance the immunogenicity 
of linked antigens (George-Chandy, Eriksson et al. 2001; D'Ambrosio, Colucci et al. 
2008) through induction of DC upregulation of CD86 and CD83 (George-Chandy, 
Eriksson et al. 2001; Isomura, Yasuda et al. 2005).  D’Ambrosio et al. showed that CTB 
could partially prevent LPS-induced maturation of monocyte derived DCs (D'Ambrosio, 
Colucci et al. 2008). Recently, we reported our that CTB conjugated to the autoantigen 
proinsulin (CTB-INS) suppressed DC surface expression of CD86 and CD83 
costimulatory molecules with a significant increase in the IL-10 synthesis and a 
suppression of IL-12/23p40 synthesis (Odumosu, Payne et al. 2010). Similar to 
D’Ambrosio’s findings, our data suggest that CTB influences DC phenotype and 
function. Furthermore, CTB may possess an intrinsic capacity to modulate either 
inflammation or tolerance depending on whether it is conjugated to an antigen or an 
autoantigen. Further studies are necessary to resolve the question of the duality of CTB 
activity as an adjuvant for inflammatory or anti-inflammatory immune responses. 
In this study, we found that CTB-GAD35 suppressed iDCs capacity to mature and 
become activated in vitro. Furthermore, our data show that the CTB-GAD35 fusion 
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protein inhibits PMA+Ionomycin induction of DC maturation as determined by a failure 
to upregulate CD86, CD83 and CD80 co-stimulatory molecules. This effect suggests that 
inoculation with the fusion protein may inhibit the progression of previously established 
autoimmunity e.g., in the case of T1DM, blockage of DC maturation could inhibit further 
development of diabetes symptoms of insulitis and hyperglycemia, a result partially 
demonstrated in earlier studies from our laboratory (Arakawa, Chong et al. 1998; 
Arakawa, Yu et al. 1999). Further, our experiments indicated that CTB-GAD35 inoculated 
DCs were inhibited in their ability to synthesize major pro-inflammatory cytokines IL-
12/23p40 and IL-6. This loss was balanced with a concomitant increase in the synthesis 
of the anti-inflammatory cytokine IL-10. The results of our recent CTB-INS studies 
establish a molecular basis for CTB-GAD35 suppression of diabetes onset in NOD mice 
(Denes, Krausova et al. 2005; Gong, Jin et al. 2007; Gong, Long et al. 2009). In earlier 
studies, we demonstrated that fusion of CTB to the autoantigen was essential for 
enhancement of immune suppression, as co-delivery of CTB and the autoantigen did not 
result in a significant inhibition of DC activation and maturation (Odumosu, Payne et al. 
2010). Together our experimental findings suggest that linkage of CTB to the autoantigen 
is key to identification of the mechanism underlying adjuvant-enhanced tolerance. 
Establishment of whether CTB-GAD35 mediated immunological suppression of DCs can 
halt or reverse T1D progression will provide the basis for understanding how this form of 
interventional therapy can be applied to prevent, halt or reverse the onset of insulitis and 
hyperglycemia in diabetes patients. 
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Abstract 
 Linkage of the pancreatic islet proteins proinsulin (INS) and glutamic acid 
decarboxylase (GAD) to the cholera toxin B chain (CTB) enhances autoantigen 
suppression of type 1 diabetes (T1D). In human tissues the CTB::INS fusion protein was 
shown to suppress dendritic cell (DC) biosynthesis of costimulatory factors required for 
the initiation of autoreactive T cell morphogenesis.  In this study, we show that 
CTB::INS/GAD autoantigen inoculated immature DCs guide T cell development in the 
direction of anti-inflammatory Th2 lymphocytes and regulatory T cells (Tregs). Further, 
our experimental findings show that CTB-pancreatic autoantigen fusion protein 
inoculated DCs suppress the proliferation of inflammatory CD4 and CD8 T lymphocytes 
thought to play a major role in the initiation of diabetes onset.  Inoculation of immature 
DCs with CTB::INS/GAD fusion proteins significantly increased cognate T cell secretion 
of immunosuppressive cytokines IL-10 and TGF-β. In contrast, fusion protein inoculated 
DCs suppressed lymphocyte secretion of the pro-inflammatory cytokines IFN-γ, IL-2 and 
IL-17. Taken together, our experimental data suggests that CTB-autoantigen fusion 
protein inoculated immature DCs guide initial stages of naïve T cell development in the 
direction of immunological tolerance while simultaneously suppressing autoreactive T 
cell development. Together the experimental results provide a plausible mechanism for 
initiation of CTB-autoantigen mediated immunological suppression of T1D in humans. 
The absence of DC apoptosis and necrosis during the course of these studies suggests that 
CTB-autoantigen fusion proteins are an effective and safe vaccination strategy for 
prevention of diabetes onset in susceptible patients. 
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Introduction 
 Type 1 Diabetes mellitus (T1D) is a chronic organ-specific autoimmune disease 
that begins in childhood and persists throughout life resulting in progressive destruction 
of the pancreatic insulin and glutamic acid decarboxylase-producing islet beta cells 
(Eisenbarth 1986; Tisch and McDevitt 1996). The continual loss of islet β-cell function 
leads to insulin deficiency and elevated blood sugar levels (hyperglycemia). The 
persistence of high blood sugar levels increases cellular oxidative stress leading to 
chronic inflammation in almost all organs of the body. Thus, the result is an increased 
risk for a variety of secondary circulatory and neural physiological complications, 
including blindness, kidney failure, heart attack, and stroke which lead to unacceptable 
levels of premature mortality (Libby, Nathan et al. 2005).  
 Previous studies have shown that partial suppression of diabetes symptoms can be 
achieved by oral delivery of small amounts of the dominant pancreatic islet autoantigens 
glutamic acid decarboxylase (GAD) and insulin (Zhang, Yuen et al. 1991; Czerkinsky, 
Anjuere et al. 1999).  However, in diabetic animals, earlier studies showed that 
suppression of insulitis and hyperglycemia could be enhanced through conjugation of 
islet autoantigens to the non-toxic B subunit of Vibrio cholerae enterotoxin (CTB) 
(Bergerot, Ploix et al. 1997; Arakawa, Chong et al. 1998; Arakawa, Yu et al. 1998; 
Arakawa,  et al. 1999).  Further experiments showed that CTB is an efficient trans-
mucosal carrier molecule for autoantigen induction of peripheral tolerance (Sun, 
Holmgren et al. 1994; Shreedhar, Kelsall et al. 2003). Experiments comparing the 
efficacy of CTB to the B subunits of several related bacterial enterotoxins revealed that 
most bacterial and plant enterotoxin B subunits possessed a similar level of efficacy for 
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enhancement of autoantigen mediated diabetes suppression (Carter, Yu et al. 2006). 
Dendritic cells (DCs) are generally thought to be the most potent of the 
professional antigen presenting cells (APC) implicated in mediating islet β-cell 
destruction in T1D. Through antigen presentation to cognate T cells, DCs play a key role 
in the onset and regulation of adaptive immune response through the priming of naïve T 
helper cells (Th0) for morphogenesis into effector T cells. In addition, a variety of pro- 
and anti-inflammatory cytokine molecules produced by DCs in response to pathogen or 
toxin attack are considered important for differentiation of T cells into autoreactive Th1 
lymphocytes, immunosuppressive Th2 cells or regulatory T (Tregs) cells (Banchereau 
and Steinman 1998). Regulation of these processes is pivotal for maintaining 
immunological homeostasis in the body (Pulendran, Smith et al. 1999; Pulendran, Kumar 
et al. 2001; Itano, McSorley et al. 2003; Kapsenberg 2003).  In T1D autoimmunity, the 
maturation of DCs in response to uptake of “self” antigens like the islet β-cell proteins 
insulin and GAD, induces the development of autoreactive CD8+ cytotoxic T 
lymphocytes (CTL) and effector CD4+ T helper (Th1) lymphocytes, as well as initiating 
B cell production of autoantibodies to these islet beta cell proteins. Consequently, in the 
non-obese diabetic (NOD) mouse, these autoreactive immune cells migrate to the 
pancreas, infiltrate the islets and secrete inflammatory cytokines such as IFN-gamma and 
IL-2.  These inflammation inducing cytokines are known to stimulate macrophage and 
CTL secretion of oxidative compounds NO, O2, H2O2 as well as inflammatory cytokines 
(IL-1 beta, TNF-alpha, TNF-beta) [5-7]. These immune responses are thought to be 
responsible for induction of chronic pancreatic inflammation (insulitis), which ultimately 
results in destruction of the islet β-cells and the production of  insufficient levels of 
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insulin to meet the growing body’s metabolic requirements for energy leading 
progressively to diabetes onset (Piccinni, Beloni et al. 1998). 
Recently, Our laboratory demonstrated that prevention of T1D onset may be 
mediated via induction of immunological tolerance resulting from DC interactions with 
CTB::proinsulin/GAD autoantigen fusion proteins (Odumosu, Payne et al. 2010). 
Inoculation of human monocyte-derived DCs with CTB-INS and CTB-GAD35 fusion 
proteins resulted in suppression of DC maturation. Further, our experimental results 
showed that CTB-autoantigen fusion proteins modulate DC cytokine secretion profiles in 
the direction of immunological tolerance while suppressing the biosynthesis of 
inflammatory cytokines IL-12 that could lead to the onset of autoimmunity (Odumosu, 
Payne et al. 2010). In response to these observations, the major objective of this study is 
to analyze the effects of CTB-autoantigen fusion protein stimulated DCs on naïve T cell 
morphogenesis and proliferation. 
 
Methods and Materials 
Expression and Purification of CTB-INS and CTB-GAD35 Fusion 
Proteins in E. coli 
 DNA fragments encoding 35bp deoxyoligonucleotide located proximal to the 
carboxyl-terminus of GAD65 –designated as GAD35 or a 258bp DNA fragment encoding 
human proinsulin (INS), were genetically linked to the carboxyl-terminus (309bp) of the 
cholera toxin B subunit (CTB), to generate the fusion gene CTB-GAD35 and CTB-INS 
respectively. The CTB–autoantigen fusion genes were cloned into the (A) configuration 
of the E. coli expression vector pRSET(A) (Invitrogen™, Carlsbad, CA), under control of 
the bacteriophage T7 promoter in order to achieve high levels of transgene expression. 
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The pRSET vector also contained an oligonucleotide encoding 6 histidines immediately 
upstream of CTB permitting isolation of the transgene product. Selective clones were 
assessed by DNA sequence analysis to confirm the in-frame linkage of CTB, CTB-INS 
and CTB-GAD35 DNA fragments (Fig 4.1). Recombinant vectors were then introduced 
into the E. coli producer strain BL21 (DE3)pLysS (Invitrogen, Carlsbad, CA) by 
electroporation for nickel affinity column isolation of the recombinant protein (Carter, Yu 
et al. 2006; Odumosu, Payne et al. 2010). 
Recombinant CTB-INS and CTB-GAD35 fusion proteins expressed in E. coli 
were purified by isolating the 6xHis-tagged protein from lysed cells using metal chelation 
chromatography. Transformed E. coli strain BL-21, was grown in 250 ml Luria Broth 
(LB) medium containing ampicillin (100mg/ml) with shaking at 37oC. While still in log 
phase of growth, protein synthesis was stimulated by addition of 90 mg isopropyl β-D-
1thiogalacto-pyranoside (IPTG), (Sigma Chemical Co. St. Louis, MO) to the bacterial 
culture. After 6 hr continued incubation at 370C, the bacterial culture was pelleted by 
centrifugation in a SA-600 rotor for 10 min, at 5,000 rpm and 4oC, in a Sorvall RC5B 
centrifuge. The cell pellet was resuspended in 1.0 ml / tube of 10 mM HEPES buffer (pH 
7.5), containing 100 mM imidazole. The cells were disrupted by sonication (3 x 10 sec 
bursts), at 10 W, with a Sonic 60 Dismembrator (Fisher Sci. Sunnyvale, CA).  The 
proteins were isolated and purified from the bacterial homogenate using a Maxwell 
Model 16 robotic protein purification system (Promega Inc. TM), according to the protein 
isolation protocol provided by the manufacturer (Promega Inc., Madison, WI). In order to 
obtain a pure protein product, the robot employs electromagnetically charged Magne-His 
Nickel-Iron alloy particles with an affinity for the 6-HIS tag linked to the N terminus of 
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the recombinant fusion proteins. Imidazole was removed from the protein mixture by 
dialysis of the preparation against 2 x 1.0 Liter, 10 mM HEPES buffer (pH 7.5), for 4 hr 
at 4oC. The purity of the isolated CTB-INS (~23.4kDa) and CTB-GAD35 protein 
(~22kDa) were determined by electrophoretic mobility analysis in a 12% polyacrylamide 
gel in comparison with protein molecular weight standards. The purified proteins were 
confirmed by immunoblot analysis and stored at -20oC until further use. 
 
Isolation and Culture of Monocyte-derived DC from Human Cord 
Blood 
Monocyte-derived dendritic cells (MDDC) were prepared from freshly collected 
human umbilical cord blood. The leukocyte fraction of cord blood obtained from normal 
healthy placenta donors (following LLU IRB approved protocols), was separated from 
red blood cell and platelet fractions by Red blood cell lysis protocol. Briefly, the cord 
blood was treated with ACK lysis buffer (0.15 M NH4Cl, 1 mM KHCO3, and 0.1 mM 
Na2EDTA) to lyse the erythrocytes. After washing the lymphocytes with Miltenyi buffer 
(PBS containing 0.5% BSA and 2mM EDTA), monocytes were isolated from the blood 
via MACS (Miltenyi Biotec) using PE-conjugated anti-CD14 and anti-PE microbeads 
(BD biosciences, San Jose, CA). The CD14+ monocytes were obtained from the total 
lymphocyte fraction by incubation with anti-CD14 PE (Phycoerythrin) (Miltenyi Biotech, 
Auburn, CA) for 10 min @ 4oC followed by incubation with anti-PE antibody conjugated 
to magnetic microbeads, for 15 min at 4oC. The cells were separated magnetically by 
passing them through the MACS column as described by the manufacturer (Miltenyi 
Biotech, Auburn, CA) (Devaraj, Glaser et al. 2006; Devaraj, Dasu et al. 2008).  The 
purity of the monocyte fraction was determined by flow cytometry in a BD FACSCalibur 
141 
flow cytometer (BD Biosciences, San Jose, CA. 
The isolated monocytes were cultured in 6 cm non-pyrogenic polystyrene culture 
plates in RPMI 1640 culture medium (Mediatech Inc. Manassas, VA, USA) in a 
humidified atmosphere of 5% CO2 at 37 °C (Preprotech, Rocky Hill, NJ). The medium 
was supplemented with 10% fetal bovine serum (FBS), 1 mM glutamine, 100 U/ml 
penicillin, 100 µg/ml streptomycin, 50 ng/ml human recombinant GM-CSF, and 10 ng/ml 
human recombinant IL-4 (ProSpec-Tany TechnoGene, Rehovot Science Park, Israel).  
The monocyte cell culture was fed every 2 days by gentle replacement of 50% of the 
medium with fresh medium. The cell cultures were kept in their original plates until 
harvested to avoid induction of DC maturation caused by mechanical stress associated 
with re-plating of the cells. The percentage of monocyte-derived iDCs (M-iDC) was 
determined directly by flow cytometry based on expression of DC-specific cell surface 
markers (CD14−HLA-DR+CD11c+) after 6 days further incubation. 
 
DC Maturation Assay and Phenotyping 
The iDCs were stimulated by the addition of CTB (10ug/ml medium), GAD35 
(10ug/ml), CTB-GAD35 fusion protein (20ug/ml) or Phorbol myristate acetate (PMA) and 
Ionomycin at 10ng/ml medium (PMA+Ionomycin), for 48 hrs at 37 degrees, 5% CO2.  
Following the incubation period, the expression of DC surface markers (CD14, CD11c, 
HLA-DR), indicating their state of activation and maturation was determined by flow 
cytometry. The gated  DC (CD14- HLA-DR+ CD11c+ ) cell population was analyzed for 
the expression of co-stimulatory factors CD86, CD83, CD80, and CD40  DC activation 
markers (BD Pharmingen, San Jose, CA USA). 
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Isolation of Naïve T cells and Incubation with Vaccine Inoculated DCs 
The leukocyte fraction from approximately 50 ml of human umbilical cord blood 
obtained from consenting normal healthy placenta donors (following LLU approved IRB 
protocols) was separated from the red blood cell and platelet fractions by a red blood cell 
lysis as described above and centrifugation at (2,000 RPM), 4oC, in a Beckman Counter 
Allegra X-15R centrifuge, equipped with an SX4750 rotor. The CD3+ T cells were 
positively selected from the cord blood leukocyte fraction using the MACS Pan T Cell 
Isolation Kit II protocol for indirect magnetic isolation of naïve T cells (Th0) from human 
blood (Miltenyi Biotec. Auburn, CA).  The purified Th0 lymphocytes were found to be > 
99% pure, as indicated by flow cytometric analysis.  The purified naïve Th0 cells were 
resuspended at a concentration of 1 X 106/ml in RPMI 1640 culture medium (Mediatech 
Inc. Manassas, VA, USA) supplemented with 10% FBS, 1 mM glutamine, 100 U/ml 
penicillin, 100 µg/ml streptomycin. Prior to addition to the Th0 cells, the iDCs were 
stimulated with CTB::INS /GAD fusion proteins as described above for 48 hrs at 370C. 
After the 48 hrs incubation, DCs from each treatment sample were washed twice with 
PBS and mixed with T cells at a DC:T cell ratio of 1:10,  DCs (1X 104 cells) + naïve T 
cells (1 X 105 cells). Each of the experimental DC-T cell cultures were incubated in 
approximately 200ul of RPMI 1640 medium supplemented with 10% of FBS, 1% L-
glutamine, and 1% penicillin/streptomycin (Sigma-Aldrich; complete medium)/well in a 
96-well microtiter plate for 6 days at 370C without changing the medium.  Early DC 
mediated T cell activation was assessed after 48 hrs of DC - T cell co-culture, by 
harvesting the cell mixture from several wells into a 2.0 ml culture tube by centrifugation 
as already described above and staining the cells with fluorescent labeled T cell markers 
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CD3, CD4, CD8, CD25, and CD69. The Treg cell populations were identified by flow 
cytometry according to the following phenotype: CD4+CD25+IL7R-.  The cells were 
harvested from the DC:Th0 cell co-cultured samples as previously described above and 
surface stained for T cell markers CD3, CD4, CD8, CD25 and CD127. Intracellular 
staining for the transcriptional activator Foxp3 was also performed as described below to 
allow for additional Treg characterization. The proliferation of T cells was measured by 
dilution of carboxyfluorescein diacetate, succinimidyl ester dye (CFSE) after 6 days 
incubation at a final concentration of 3µM CFSE and by upregulation of intracellular Ki-
67, a transcription factor upregulated in proliferating lymphocytes. (The CFSE dye is 
incorporated into the cell membrane and becomes diluted upon successive cell divisions). 
 
Intracellular Cytokine and KI-67 Measurement 
A total of 106/ml T cells were used each intracellular cytokine assay. After 48 hrs 
DC: T cell co-culture, the cells were incubated for an additional 8 hrs with 3 µM 
monensin for analysis of intracellular cytokines. Intracellular staining for cytokines was 
performed according to the manufacturer’s instructions (Caltag, CA). The T cells were 
washed and surface stained with fluorescently labeled CD4 and CD25 antibodies, fixed, 
permeabilized, and stained for detection of intracellular cytokines IFNγ, TGF-β, IL-17, 
IL-2 and IL-10. After washing, the cells were resuspended in 1% paraformaldehyde and 
analyzed for the presence of intracellular cytokines using the MACSQuant flow 
cytometer. Intracellular analysis of Ki-67 for cell proliferation was also done as described 
for intracellular cytokines. 
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Flow Cytometric Analysis 
For examination of DC surface markers, the cells were surface stained with 
antibodies anti-CD86-FITC, anti-CD83-PE, anti-CD40-FITC, anti-CD80-PE, anti-HLA-
DR-PerCP anti-CD14-APC anti-mouse IgG1-FITC, anti-mouse IgG1-PE, anti-mouse 
IgG1-HLA-DR, and anti-mouse IgG1-APC (BD Pharmingen, San Hose, Ca); 7-Amino-
actinomycin D (7-AAD) was used to assess the viability of the collected cells.  To 
analyze T cell populations, anti-CD4-PE, anti-CD127-PE, anti-IL-10-PE, anti-CD3-
PerCP, anti-CD8-APC-Cy-7, anti-IFNγ- Bio-SA-APC, anti-IL-4-Biotin-SA-APC, anti-
CD25-Biotin-SA-APC, anti-TGFβ-PE-Cy-7 fluorescent tagged antibodies were used.  
The fluorescent tagged antibodies were obtained from eBioscience Inc, and Biolegend, 
Inc., San Diego, CA, USA. The fluorescence intensity indicated on all flow histograms is 
shown on a log scale.  An Isotype control was run with each set of samples and was used 
to define negative and positive cell populations. All samples were analyzed using a 
Miltenyi MACSQuant flow cytometer (Miltenyi Biotec.).  
 
Statistical Analysis 
Statistical analyses of experimental treatment groups were performed using a one-way 
analysis of variance method (ANOVA).   Cell population percentages and fluorescence 
intensity values were presented as the mean ± 95% confidence interval.  A p value of < 
0.05 was considered to be statistically significant. 
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Figure 4.1 Construction of the CTB-INS Fusion Gene and Isolation of the Gene Product. 
(A). Plasmid map of the E. coli expression vector pRSET A (Invitrogen™, Carlsbad, 
CA), carrying the CTB-INS or the CTB-GAD35 fusion gene.  (B)  Map of the cholera 
toxin B subunit– proinsulin autoantigen gene fusion CTB-INS (567bp). (C) The cDNA 
fragment of cholera toxin B subunit (CTB) was fused at the C-terminus to the 5kDa 
pancreatic islet autoantigen glutamic acid decarboxylase (GAD).  The expression vectors 
pRSET-CTB-INS and CTB-GAD are under the control of the bacteriophage T7 promoter 
containing an oligonucleotide region encoding 6 histidine amino acid residues 
immediately 5’ upstream of the CTB DNA sequence. The recombinant plasmids were 
introduced into the E. coli recipient strain BL21 (DE3) pLysS, for optimum fusion 
protein expression and for nickel binding mediated isolation of the recombinant protein 
using a Maxwell 16 TM protein isolation robot (Promega Inc, Madison, WI, USA). 
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Results 
CTB-INS and CTB-GAD35 Fusion Protein Inoculated DCs Suppress T 
cell Activation 
We investigated the effect of CTB-autoantigen inoculated DCs on Th0 cell 
morphogenesis. Allogeneic T cells  (106),  preactivated with anti-CD3/CD28 monoclonal 
antibodies for 48hrs were cultured with CTB, INS, GAD, CTB-INS, CTB-GAD35, PMA 
and Ionomycin inoculated DC for 3 days and analyzed for the expression of CD69 (the 
earliest inducible cell surface glycoprotein acquired during lymphoid activation).  The T 
cells cultured with CTB-INS and CTB-GAD35 inoculated DCs showed a significantly 
reduced capacity for expression of CD69 activation marker in contrast to Th0 cells 
cultured with a single autoantigen or PMA+Ionomycin stimulated DCs (p<0.05)(Fig 4.2). 
This experimental data suggests that CTB-autoantigen inoculated DCs appear to suppress 
early T cell activation. 
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Figure 4.2: CTB-autoantigen fusion protein inoculated DCs suppress anti-CD3/CD28 Ab 
stimulated T cell expression of CD69 protein.  (A) Representative flow cytometry plot 
showing the presence of CD4+ and CD8+ T cell populations after gating for CD3+ T 
cells. (B). FACS plots of T cells expressing CD69+ protein after gating for CD4+ (Top) 
and CD8+ T cells (Bottom).  
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Figure 4.2.  Continued. 
(C) Bar graph representing the percent of CD69+ activated CD4+ and CD8+ T cells   
following incubation of naïve T cells with DCs inoculated with CTB-autoantigen fusion 
proteins or autoantigen alone. The data presented represent the means and SEM for 4 
individual experiments. The asterisk (*) indicates the presence of a statistically 
significant reduction in T cell synthesis of CD69 T cell activation marker protein 
(p<0.05) for CTB-autoantigen fusion treated samples in comparison with autoantigen 
alone treated samples.  
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CTB-INS and CTB-GAD35 Fusion Protein Inoculated DCs Induce 
Generation of T Cells with Reduced Proliferative Capacity 
To evaluate the ability of CTB-autoantigen inoculated DCs to inhibit T cell 
proliferation, CD3+ T cells were co-cultured with CTB, INS, GAD, CTB-INS, CTB-
GAD35 and PMA+Ionomycin following their initial activation with PMA+Ionomycin and 
anti-CD3/CD28 antibodies   for 48 hrs at 370C. The T cells were labeled with CFSE and 
KI-67 respectively.   As shown in Fig.4.3, Th0 cells co-cultured with CTB-INS and CTB-
GAD35 inoculated DCs consistently inhibited the proliferation of CFSE labeled Th0 cells 
and the expression of transcription factor KI-67 in comparison with Th0 cells co-cultured 
with INS or GAD autoantigens alone or with PMA+Ionomycin activated DCs that 
demonstrated multiple divisions in the presence of CFSE (P<0.05) (Fig 4.3). 
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Figure 4.3: Shows CD 3+ naïve Th0 cell stimulation following inoculation with CTB-
autoantigen inoculated DCs.   
Naive T cells isolated from umbilical cord blood were incubated with anti-KI-67 
antibodies and after 4 days additional incubation in culture medium the cells were 
analyzed by flow cytometry to assess the degree of cell proliferation based on synthesis 
of KI-67 protein in CD4+ T helper cells (A), or CD8+ cytotoxic T cells (B). The bars in 
each graph represent the mean and SEM of three independent experiments for each T cell 
treatment.  Based on the synthesis of KI-67, naïve Th0 cells incubated with CTB-
INS/GAD autoantigen fusion protein inoculated DCs showed a significant reduction in 
proliferative capacity in comparison with PMA and Ionomycin inoculated and anti- 
CD3/CD28 Ab activated T cells. Asterisks (*) over the bars represent a significant 
difference in the expression of CD69+ in Th0 cells incubated with DCs inoculated with 
CTB-autoantigen fusion proteins in comparison with T cells incubated with DCs 
inoculated individually with INS or GAD autoantigens (p<0.05). (C) To identify the 
number of cell divisions that occur during T cell proliferation, following incubation with 
CTB-autoantigen fusion protein inoculated DCs, negative control and CD3+, activated T 
cell samples were labeled with CFSE dye and after 6 days incubation in culture medium, 
the individual cultures were analyzed by flow cytometry for incremental reductions in 
CFSE dye staining intensity signifying the presence of successive cell divisions. The 
histogram represents reductions in CFSE dye fluorescence intensity commensurate with 
successive cell divisions detected following proliferation of the T cells in each 
experimental treatment.   
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CTB-autoantigens Induce CD4+ T regulatory Cells 
 In the next set of experiments, we investigated the ability of CTB-autoantigen 
stimulated DCs to induce suppressor CD4 + regulatory T cells (Tregs), based on the 
increased recognition of their importance in mediating tolerance and protection from 
autoimmune diseases (Sakaguchi, Sakaguchi et al. 1995). Therefore, DCs stimulated with 
fusion proteins or activated with PMA+Ionomycin were cultured with CD3+ T cells 
previously activated with anti-CD3/CD28 antibodies. After five days incubation with the 
fusion proteins, the cell cultures were harvested and analyzed for the proliferation of 
CD4+ CD25+ IL7- regulatory T  cells (Tregs), based on the level of Ki-67 expression 
(Fig 4.4). Our experimental results showed increase in expansion of Treg populations 
based on Ki-67 expression in CTB-INS and CTB-GAD35 inoculated DCs, was 
significantly upregulated by 4 fold and 2.5 fold in comparison with INS and GAD35 
inoculated DC cultured with T cells (p<0.05).  However, The expression of Foxp3 was 
not found to differ among all of the Treg populations gated for the CD4+CD25+IL-7- 
phenotype. 
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Figure 4.4: CTB-autoantigen inoculated DCs induce T regulatory cell (Treg) 
proliferation.  
 (A) Dot plot showing expansion of Tregs by staining the DC:T lymphocyte mixture with 
CD4+, CD25+, IL-7R-, and intracellular Ki-67 fluorescent-labeled antibodies. The 
proliferation of Tregs was measured by flow cytometric determination of the percentage 
of activated Tregs expressing Ki-67.  Differences in Treg population expansion were 
determined by ANOVA (p<0.05). (B) The bar graph represents the percentage of Treg 
cells expressing Ki-67 transcription factor as an indicator of cell division. The columns 
represent the means and SEM of three independent experiments. The asterisks (*) 
represent significant differences in the expression of Ki-67 (cell proliferation) in Tregs 
cells for T cells incubated with CTB-autoantigen fusion protein inoculated DCs in 
comparison with T cells incubated with DCs inoculated with the single autoantigens 
alone (p<0.05). 
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CTB-autoantigen Stimulated DCs Direct Cognate T cells to Increase 
IL-10 or TGF-β Cytokine Production 
 To examine the ability of CTB-autoantigen stimulated DCs to modulate T cell 
cytokine production, CD3+ T cells were co-cultured with CTB, INS, GAD, CTB-INS, 
CTB-GAD35 or PMA+Ionomycin inoculated DC, following initial activation of the naïve 
T cells with anti CD3/CD28 antibody and PMA+Ionomycin.  Intracellular cytokine 
production in the DC inoculated T cells was determined following incubation of the 
cultures in medium containing 3 µM  monensin for the last 8 hrs of the incubation period. 
In comparison with INS and GAD35 inoculated DC treated T cells, both CTB-INS and 
CTB-GAD35 stimulated T cells produced significantly higher amounts of 
immunosuppressive IL-10 and TGF-β cytokines (p<0.05) and significantly reduced 
amounts of proinflammatory IFN-γ, IL-2 and IL-17 (p<0.05). Incubation of naïve T cells 
with DCs activated by CTB-INS induced significantly higher levels of IL-10 
biosynthesis, while T cells incubated with DCs activated by CTB-GAD35 fusion protein 
resulted in significantly increased levels of TGF-β biosynthesis (P<0.05). Taken together, 
these experimental results suggest that CTB-autoantigen inoculated DCs may induce 
differentiation of immunosuppressive Th2 and Treg populations with CTB-INS and 
CTB-GAD35 inoculated DCs stimulating T cell biosynthesis of cytokines normally 
synthesized by Tr1 and Th3 Tregs respectively. These experimental results indicate that 
CTB-autoantigen inoculated DCs phenotype are likely associated with immunological 
tolerance and T cell regulatory activities. 
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Figure 4.5: CTB-autoantigen stimulated DCs direct cognate T cells to increase IL-10 and 
TGF-β anti-inflammatory cytokine production. The CD3+ T cells isolated from umbilical 
cord blood were co-cultured with CTB, INS, GAD, CTB-INS, CTB-GAD35 or 
PMA+Ionomycin, following initial stimulation of the naïve T cells with 
PMA+Ionomycin +antiCD3/CD28 antibodies for 48 hrs.  Monensin (0.3 µM), was added 
to each cell culture sample during the last 8 hrs of incubation to permit accumulation of 
cytokine levels within the DC incubated T cells prior to flow cytometric measurements of 
sequestered T cell cytokine levels.  (A) The overlapping histograms show T cell 
populations synthesizing IL-10, TGF-β, IFN-γ, IL-2 and IL-17 cytokines following T cell 
incubation with DCs previously inoculated with CTB, INS, GAD, CTB-INS, CTB-
GAD35 or PMA+Ionomycin in comparison with the control cultures (T cells incubated 
with immature DCs). The CTB-INS and CTB-GAD35 stimulated T cell samples 
synthesized significantly higher amounts of immunosuppressive IL-10 and TGF-β 
cytokines (p<0.05) and significantly diminished amounts of proinflammatory IFN-γ, IL-2 
and IL-17 (p<0.05). (B) The graphs indicate   mean fluorescence intensity levels 
representing T cell biosynthesis of IL-10, TGF-β, IFN-γ, IL-2 and IL-17 cytokines 
following their incubation with DCs inoculated with the autoantigen fusion proteins 
described above. Statistical significance among the T cell cultures was calculated based 
on P<0.05. 
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Discussion 
Previous studies have demonstrated the major role played by DCs in the induction 
and maintenance of immune tolerance (Steinman, Turley et al. 2000; Wakkach, Fournier 
et al. 2003). The results of our previous CTB-INS animal studies have established a 
molecular basis for CTB-INS and CTB-GAD35 fusion proteins in suppression of Type 1 
diabetes (T1D) onset in NOD mice (Denes, Krausova et al. 2005; Gong, Jin et al. 2007; 
Gong, Long et al. 2009). In these studies, we demonstrated that the fusion of CTB protein 
to the autoantigen was required to achieve a dramatic enhancement of immune 
suppression.  Following these animal studies, our human ex vivo studies revealed that co-
delivery of CTB + the autoantigen did not result in a significant inhibition of DC 
activation and maturation (Odumosu, Payne et al. 2010).  Taken together our 
experimental findings suggest that linkage of CTB to the autoantigen is key to the 
identification of the mechanism underlying adjuvant-enhanced autoantigen mediated 
immunological tolerance. However, cellular and molecular mechanisms underlying 
multi-component vaccine suppression of T1D remain unidentified.  The dominant role of 
DCs in the decision required to induce inflammation or to activate immunotolerance 
implicates this APC resides at the point of earliest initiation of CTB-autoantigen 
mediated suppression of diabetes onset. To confirm this observation, we assessed the 
interaction and outcome of CTB-autoantigen stimulated DCs on naïve T cells. Our 
experimental data suggests that CTB-autoantigen inoculated DCs induce the ex vivo 
differentiation of IL-10 and TGF-β producing T cells that possess limited proliferative 
capacity. This experimental result is in agreement with previous experiments describing 
the immunosuppressive nature of Th2 and regulatory Tr1 and Th3 cells (Levings, Gregori 
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et al. 2005; Battaglia, Stabilini et al. 2006; Roncarolo, Gregori et al. 2006).  
In this ex vivo study, human monocyte-derived DCs incubated with CTB-
autoantigen fusion proteins generate Tregs from CD3+ T cells. In comparison with Tregs 
incubated directly with INS or GAD35 autoantigens alone, T cells incubated with CTB-
INS/GAD inoculated DCs generated more than a 2.5 fold increase in proliferation 
compared to control samples and PMA+Ionomycin inoculated samples. These 
experimentally identified immunosuppressive properties are in agreement with those 
described for the performance and functions of Tr1 and Th3 regulatory T cells. 
Traditionally, a marker for specific identification of Tregs is expression of the 
forkhead box transcription factor (FOX) P3, possibly because foxp3 gene transfer was 
shown to convert naïve CD4+CD25- T cells into functional regulatory T cell populations 
(Fontenot, Gavin et al. 2003; Hori, Nomura et al. 2003; Khattri, Cox et al. 2003). While 
FOXP3 protein biosynthesis can be used to quantify Treg populations and assess their 
purity, FOXP3 is an intracellular protein that requires cell fixation and permeabilization 
prior to detection. This requirement makes it impossible to use FOXP3 as a marker for 
identification of live Treg cell populations for functional studies. Of particular interest 
would be the identification of a cell surface marker that correlates with FOXP3 and 
represents a specific marker for regulatory T cells that is independent of Treg CD25 
expression.  Earlier reports by Liu et al. in 2006 (Liu, Putnam et al. 2006) and Seddiki et 
al (2006) showed that differential expression of CD127 (the α-chain of the IL-7 receptor) 
enables separation of human CD4+CD25+CD127- Tregs based on flow cytometry. Both 
studies indicated that CD127- cells were FOXP3 positive in human peripheral blood and 
that CD127 was a better marker than CD25 in mice, with most CD4+Foxp3 Treg cells 
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having a CD127- phenotype. In addition, the functional immunosuppressive activity of 
CD127- Treg populations and its absence in the presence of the CD127+ marker protein 
was also clearly demonstrated (Liu, Putnam et al. 2006). In this study, we have identified 
Treg cell populations based on flow cytometric identification of the CD4+CD25+CD127- 
phenotype, the cytokines that they synthesize and their proliferative capacity (a sign of 
their expansion in response to DC activation). In confirmation of the observations of 
Seddiki and Liu, the CD4+CD25+CD127- Treg populations analyzed in our study were 
also found to be Foxp3+ (data not shown). 
Several observations suggest that Tr1 cells are involved in CTB-INS/GAD 
maintenance of DC –T cell mediated peripheral tolerance ex vivo. Certain regulatory T 
cell subsets (Tr1) play an important role in modulating immune responses during the 
progression of autoimmunity, based on the reduction in IL-10 producing CD4+ cells 
observed in the synovial tissue and peripheral blood of rheumatoid arthritis and 
autoimmune hemolytic anemia patients (Yudoh, Matsuno et al. 2000; Hall, Ward et al. 
2002).  
Perhaps the most significant class of novel effector cell types involved in both 
human and mouse organ specific autoimmunity models are the recently identified Th17 
cells that secrete the pro-inflammatory cytokine IL-17 (Fujino, Andoh et al. 2003; Nakae, 
Nambu et al. 2003; Komiyama, Nakae et al. 2006). This inflammatory cytokine was first 
detected in the serum and tissues of patients with autoimmune diseases such as multiple 
sclerosis (MS), systemic lupus erythematous (SLE) and rheumatoid arthritis (RA) (Wong, 
Ho et al. 2000; Tzartos, Friese et al. 2008). Blockade of IL-17 was shown to prevent the 
development of Experimental Autoimmune Encephalitis (EAE ), while IL-17 knockout 
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mice showed resistance to the development of EAE and collagen-induced arthritis (CIA) 
(Nakae, Nambu et al. 2003; Hofstetter, Ibrahim et al. 2005). These experimental results 
suggest that regulation of Th17 differentiation and function may prove to be a potential 
therapeutic target for organ specific autoimmune diseases.  Our recent experiments 
identified CTB-GAD35 suppression of DC synthesis and secretion of IL-6, a pleiotropic 
cytokine involved in regulating the balance of IL-17 producing Th17 cells and Treg cells 
(Bettelli, Carrier et al. 2006; Mangan, Harrington et al. 2006).  Further, IL-6 was found to 
be an effective target for down-regulating the differentiation of Th17 cells as a 
therapeutic treatment for autoimmunity (Nishimoto, Terao et al. 2008; Yokota, Imagawa 
et al. 2008). In this study, our experimental findings demonstrate that CTB-INS and 
CTB-GAD35 suppress T cell biosynthesis of IL-17. This experimental result in 
combination with CTB-GAD35 inhibition of DC IL-6 biosynthesis may be critical 
elements in the elucidation of cellular mechanisms responsible for CTB-autoantigen 
mediated immune suppression of T1D autoimmunity. 
In conclusion, this study supports the hypothesis that CTB-autoantigen fusion 
protein modulated DCs stimulate the morphogenesis of immunosuppressive human T 
cells ex vivo, largely through inhibition of DC maturation, synthesis of inflammatory 
cytokines and by stimulation of DC biosynthesis of anti-inflammatory cytokines. 
Although many experimental strategies have been adopted to induce or expand 
immunosuppressive cells to inhibit the immune responses underlying autoimmune 
pathologies, immunological tolerance can be maintained by selected adjuvant autoantigen 
fusion vaccine administration through the induction of the anti-inflammatory cytokine IL-
10 (Arakawa, Chong et al. 1998). In a separate in vivo study, our laboratory recently 
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demonstrated that a combinatorial therapy of CTB-GAD35 + IL-10 is able to completely 
suppress the onset of type 1 diabetes in NOD mice (Denes, Fodor  et al. 2010). Our 
experimental results suggest that ex vivo inoculation of human DCs with adjuvant – 
diabetes autoantigen fusion proteins favors immunological suppression of diabetes onset  
and suggests that mechanisms of immunological tolerance responsible for multi-
component vaccine suppression of diabetes onset are comparable in humans and animals 
and most importantly provides a readily available ex vivo experimental system closely 
resembling in vivo conditions for analysis of improved therapeutic strategies for 
resolution of human diabetes autoimmunity. Experiments involving CTB-INS/GAD 
vaccine suppression of previously activated DCs may provide ex vivo evidence that the 
progression of human T1D can be safely halted to re-establish immunological 
homeostasis and thereby set the stage for pancreatic stem cell repopulation of the islets of 
Langerhans with insulin secreting “beta-like” cells that may persistently alleviate T1D in 
human patients.  
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CHAPTER 5 
CONCLUSIONS 
 The establishment of individual autoantigen mediated immunotolerization 
strategies has provided a basis for assembly of individual therapeutic molecular 
components into a multi-component vaccine for immunological suppression of Type 1 
Diabetes (T1D).  These multi-component vaccine strategies appear at first glance to be 
safer, more effective in immune suppression and more durable than application of the 
individual vaccine components alone. Early experimentation with individual molecular 
therapeutic strategies was shown to provide short-term suppression of organ specific 
autoimmunity (Weiner, Zhang et al. 1991; Zhang, Davidson et al. 1991). However, few 
of these individual therapies were shown to demonstrate effective, safe and persistent 
protection against disease onset and progression (Hutchings and Cooke 1998).  When 
linked to a pathogen or foreign antigen, the weak protein adjuvant cholera toxin B 
subunit (CTB) was often found to stimulate antigen-specific mucosal immunity and to 
strengthen immune responses against pathogen proteins. Experimental evidence 
suggested that CTB stimulation of innate immunity was initiated through activation of 
immature dendritic cell  (iDC) signal transduction pathways that lead to DC maturation. 
The stimulation of DC maturation by CTB resulted in DC synthesis and secretion of 
inflammatory cytokines and chemokines such as IFN-γ, IL-2 and CTLA4 responsible for 
DC migration to the spleen or peripheral lymph nodes where DC secreted inflammatory 
cytokines that assisted in the guidance of cognate naïve Th0 helper cell differentiation 
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into immunostimulatory effector Th1 lymphocytes and cytotoxic T cells.  
 However, when CTB was linked to an autoantigen such as insulin in T1D, it often 
stimulated autoantigen mediated suppression of organ specific autoimmunity many fold, 
achieving levels of immunological tolerance approaching that required for clinical 
intervention. This exception of CTB–autoantigen fusion protein enhancement of immune 
suppression to the expected paradigm of enhanced immunity emphasizes the novelty of 
the CTB as an immunomodulatory molecule for development of therapeutic vaccines. 
These apparent counter-intuitive attributes emphasize the extent to which the mechanisms 
underlying CTB stimulation and suppression of immunity remain as yet under studied. 
Combinatorial vaccines involving oral delivery of the CTB linked to pancreatic 
autoantigens such as proinsulin and GAD, were shown to provide significant increases in 
enhancement of autoantigen mediated suppression of Type 1 diabetes symptoms in 
contrast with inoculation of prediabetic mice with glutamic acid decarboxylase (GAD) or 
proinsulin alone (Arakawa, Chong et al. 1998). More recent combinatorial DNA 
vaccination experiments including genes encoding CTB-GAD in combination with the 
immunosuppressive cytokine IL-10 have demonstrated complete suppression of diabetes 
onset in non-obese prediabetic (NOD) mouse model of T1D.  Thus, it is now clear that 
combinatorial vaccination strategies can completely prevent diabetes onset in genetically 
susceptible mammals with no detectable undesirable effects.  The experimental studies 
presented here emphasize the possibilities for increased vaccine effectiveness in 
suppression of diabetes onset based on the development of combinatorial vaccination 
strategies.  
  In chapters 2 and 3 of this dissertation, the experimental data suggest that fusion 
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of CTB to autoantigens appears to activate genes that stimulate DC synthesis of anti-
inflammatory cytokines such as IL-10 that suppresses DC maturation in combination 
with inhibition of DC biosynthesis of co-stimulatory factors CD86, CD83 and CD80 
required for naïve Th lymphocyte activation. Further, CTB-autoantigen fusion protein 
inoculated DCs were shown to secrete reduced levels of inflammatory cytokines IL-12 
and IL-6 while at the same time upregulating biosynthesis of the anti-inflammatory 
cytokine IL-10.  In chapter 4, the incubation of DCs with adjuvant-autoantigen fusion 
proteins was found to enhance their guidance of naïve Th0 cell morphogenesis and 
proliferation into anti-inflammatory Th2 lymphocytes and regulatory T cells capable of 
inhibiting diabetes onset.  In addition, it became clear from the cytokine analysis studies 
that multi-component vaccine suppression of DC maturation lead to the suppression of 
autoreactive Th1 and Th17 inflammatory lymphocyte development, suppressing their 
potential for initiation of T1D insulitis and hyperglycemia.  These ex vivo human immune 
cell vaccination experiments establish a basis for identification of mechanisms 
responsible for vaccine inhibition of human diabetes progression and the way for in vivo 
analysis of multicomponent vaccine strategies for rescuing the large numbers of diabetes 
patients in which the disease has already progressed to hyperglycemia,    
 Further, these experiments establish a basis for development of safer and more 
effective treatments for supplementation or replacement of current nonspecific 
immunosuppressants, anti-inflammatory steroids or interventional therapies like islet 
transplantation, which can increase patient vulnerability to infection and other 
complications.  These experiments provide a basis for development of safer and more 
effective vaccine strategies for preventing diabetes onset and progression in patients that 
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can lead to restoration of immunological homeostasis and euglycemia in T1D patients.  
  Several studies have reported that oral administration of autoantigens may 
actually exacerbate autoimmune disease (Genain, Abel et al. 1996; Bellmann, Kolb et al. 
1998; Blanas and Heath 1999).  Although no instances of autoimmune disease have been 
reported following application of recombinant protein, experiments remain to be 
performed that will determine the optimum dose and frequency of immuno-modulated 
autoantigen delivery required to achieve the maximum protective efficacy.   
 An immediate major benefit of CTB adjuvant enhanced vaccine technology 
presented in this dissertation will be delivery of mucosal subunit vaccines for protection 
of populations in countries suffering health care disparities. To this end, our group has 
focused on a promising approach to the production of an autoimmune disease protective 
vaccine generated in edible transgenic plants (Carter, Odumosu et al. ; Chong, Roberts et 
al. 1997; Arakawa, Yu et al. 1998; Arakawa, Yu et al. 1999). One of the major limitations 
of this is the possibility for initiation of autoimmune disease symptoms in disease-free 
individuals who accidentally consume autoantigens linked to a strong bacterial adjuvant. 
Ethical issues regarding recombinant DNA mediated immunotherapy are more likely to 
subside as the public becomes more adequately informed concerning the safety of 
genetically modified organisms (GMO).  With each successful clinical trial, confidence 
in the expediency of using edible vaccines for disease prevention in the population will 
increase in the scientific, corporate and private sectors. 
Nonetheless, the molecular and biochemical studies presented within this doctoral 
dissertation, demonstrate that CTB-INS/GAD suppression of autoimmune responses 
provides a basis for development of pluripotent adult or totipotent embryonic stem cell 
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repopulation of the pancreas with insulin producing beta cells for restoration of 
euglycemia and return of the T1D patient to a durable state of immunological 
homeostasis.  The further establishment of complete immune suppression of diabetes will 
help to ensure both preventive and interventional therapy for T1Din patients suffering 
from this life-long chronic inflammatory autoimmune disease.  This application in 
combinatorial vaccination protocols may prove to be a plausible direction for effective 
immune suppression of additional organ-specific autoimmune diseases such as, Graves's 
disease, Hashimoto’s thyroiditis, rheumatoid arthritis, multiple sclerosis, myasthenia 
gravis and uveitis.
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APPENDIX A 
ISOLATION OF LEUKOCYTES FROM CORD BLOOD 
 Collection of umbilical cord blood from Cesarean section patient at Loma Linda 
University Medical Center:  
 Cord blood is collected from patients who had just undergone Caesarean section 
surgical procedure.  25 ml of cord blood is usually collected by Ineavely Baez in a 50ml 
conical tube under specified IRB approved protocols. Stem cells CD34+ cells which 
make up 1% of PBMNC are isolated by Magnetic Separation using Micro beads. The 
remaining cell populations which are CD34- are frozen in Growth Media containing 
RPMI 1640 supplemented with 10% FBS, 1 mM glutamine, 100 U/ml penicillin, 100 
µg/ml streptomycin (D10).  
 
Procedure 
I. Note time blood collected in notebook. 
II. Dilute CB 50/50 with Hanks (HBSS) in 50 ml tube. 
III. For each full tube of Hanks/CB mixture prepares two 50 ml tubes 
containing 25 ml of Ficol. 
IV. Gently layer 25 ml of Hanks/CB mixture over Ficol being careful 
not to disturb the interface between the blood and the Ficol 
(holding tube at an angle may help). 
V. Spin in centrifuge at room temp, 2000 RPM; brake off, for 30 
minutes. 
VI. Remove tubes from centrifuge being careful not to disturb buffy 
layer of mononuclear cells that are located at the interface between 
the serum (on top) and the Ficol (on bottom) 
VII. Using a pipette remove and discard serum and from top of buffy 
layer leaving about 1/4 to 1/2 inch of serum on top of off buffy 
layer.  
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VIII. Place pipetter at the top of serum and remove remaining serum 
along with all of buffy layer and transfer to a clean 50 ml tube.  Be 
sure that pipetter is at surface of liquid Ficol is not aspirated from 
under buffy layer. Add Hanks to fill tube to top.  
IX. Spin in centrifuge at room temp, 1500 RPM, brake on low, for 10 
minutes. 
X. Aspirate off supernatant. Resuspend cells in 10 mls of PBS and 
then transfer cells to pellet in next tube.  Resuspend cells and 
transfer to next tube, until all cells are in one 50 ml tube.  Wash 
remaining cells from empty tubes by repeating the process with 10 
additional mls and which should be placed in 50 ml tube with cells.  
XI. Fill 50ml tube with cells to top with PBS and spin in centrifuge at 
room temp, 1500 RPM, brake on low, for 10 minutes. 
 
IF FICOLL LAYER WAS EXTREMELY BLOODY PERFORM ORTHOLYSIS 
(SEE BELOW) AT THIS POINT. 
XII. Aspirate off supernatant and resuspend cells in 10 ml of PBS.  
Transfer to 15 ml tube.  Wash 50 ml tube with 1 ml of PBS and 
transfer wash to tube with the rest of cells. 
XIII. Count by diluting 10 ul of cells in 990 (1:100) or 90 (1:10) ul of 3 
% acetic acid. 
XIV. Spin remainder of tube in centrifuge at room temp, 1500 RPM, 
brake on low, for 5 minutes. 
XV.  Aspirate supernatant off cells, and resuspend in 300 ul of Miltenyi 
buffer per 108 cells.  
XVI. Add 100 ul of solution A1 per 108 cells counted in step 13 above 
and incubate at 4oC for 15 minutes. 
XVII. Add 100 ul of Solution A2 per 108 cells and incubate an additional 
15 minutes. 
XVIII. Add Miltenyi buffer to 10 ml and spin down (5 minutes at 1500 
RPM), aspirate off buffer. 
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XIX. Resuspend in 400 ul Miltenyi buffer per 108 cells and add 100 ul of 
reagent B (beads) per 108 cells and incubate at 4 oC for 15 minutes.   
XX. Add Miltenyi buffer to 10 ml, spin down and pull off supernatant.  
Resuspend cells in 1 ml of Miltenyi buffer very well using 1 ml 
pipet. 
XXI. While beads are spinning set up magnetic apparatus: --Place 
column in magnetic (2 prongs out) being careful to keep tip of 
column and plunger sterile.--place pre-filter on top of column--
Add .5 ml of Miltenyi buffer to prefilter and pipette up and down 
until liquid goes through to column .  Let drip through column to 
15 ml centrifuge tube set up in Styrofoam rack.   
XXII. Add cell suspension to top of column and let cells run through. 
COLLECT RUN THROUGH (CD34-CELLS) IN A CLEAN 
TUBE 
XXIII.  TO ELUTE CD34+ CELLS: Wash 3 times by adding .5 ml of 
buffer to top of column and letting run through. 
XXIV. Get 1.2 ml of buffer in pipetman and place in column while 
holding it over 4 ml collection tube.  Being careful to keep end of 
plunger sterile put in top of column and plunge down.   
XXV.  If high purity needed plunge cells into a second column which has 
been placed in magnet.  
 
 
Ortholysis 
 Aspirate off supernatant.  Lyse red blood cells by resuspending cells in 10 ml of 
lysis buffer and incubating for 10 minute at 37 oC (water bath).  After incubation fill tube 
to top with HBSS.    
 Spin down cells (5 minutes at 1500 RPM), aspirate off supernatant, resuspend 
cells in 10 ml of PBS and transfer to 15 ml tube. Dilute a small sample 1:10 in PBS for 
counting.  Continue at step 14 in above protocol. 
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TIME:  5-6 hours at first, later 3-4 hours 
 
NOTE:  From one tube of cord blood can get  
            ~1 X 108 white blood cells 
              1-2 X 106 CD34+ (approximately 1% of cord blood) 
              1 X 104 CD38- CD34+ 
 
 
 
MATERIALS: 
 
Red Blood Cell Lysis Buffer 
Dissolve the following in 800ml distilled H2O 
 8.3g NH4Cl 
 1.0g KHCO3  
 1.8ml of 5% EDTA  
Filter sterilize through 0.2um filter  
Bring volume to 1000ml with distilled H2O 
Miltenyi buffer (Mini MACS buffer) --.5% BSA, 5 mM EDTA, PBS 
 For 250 ml: 12.5 ml 10% BSA--culture grade (or 16.7 ml of 7.5% BSA) 
   2.5 ml of 0.5 M EDTA 
               1X PBS to 250 ml  
Filter-sterilize and then wrap parafilm around top of filter to seal degas for 1 hour 
prior to use.  Store tube at 4 oC. 
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APPENDIX B 
ISOLATION OF CD14+ MONOCYTES FROM CD34- CORD BLOOD 
 
Frozen cord blood CD34-cells are thawed in thawing medium containing 25 ml of 
any medium containing at least 10% serum (D10, R10, etc), 100 units of sterile heparin 
(100 ul of 1000 U/ml stock) and 750 Units of DNAase (250 ul of 3000U/ml stock Sigma 
#D-5025 in water) For 150,000 Unit bottle dissolve in 50 ml of sterile water and aliquot. 
 
 
Procedure: 
I. Thaw one 2 ml vial of frozen cells quickly in water bath. 
II. Rinse vial with alcohol and dry. 
III. Place cell suspension in 50 ml centrifuge tube. 
IV. Add 25 ml of thawing medium drop by drop swirling after each 
addition.  Should take about 2-3 minutes to dilute sample. 
V. Place cells at 37 oC for 1 hour. 
VI. Spin down cells in centrifuge and then wash with 5 ml PBS or 
Miltenyi buffer (Bechmann Counter Allegra X-15R centrifuge, 
SX4750 RPM 1500 for 8 min @ 4 oC). 
VII. Aliquot 10 ul of cells for counting.  
VIII. Count cells by hemocytometer (diluting 1:2 with trypan 
blue)  multiply by appropriate volume:(# cells in one frame) X 
(trypan blue dilution—usually 2) X (104 ) X (# of mls of 
cells) 
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IX. Aspirate off supernatant after washing cells transfer cells to a 
FACs tube and wash again in 2 ml Miltenyi Buffer (5 minutes@ 
1500RPM). 
X. Aspirate off supernatant.  
XI. Resuspend cells in 100 ul of Miltenyi Buffer for each 50 million 
cells.  
XII. Add 10 ul of CD14-PE antibody for each 100 ul of cell 
suspension.  
XIII. Incubate 10 minutes in Fridge. 
XIV. Add 4ml Miltenyi Buffer to fill the tube— 
XV. Aspirate supernatant and resuspend at 5X107 cells per 80 
ul of Miltenyi buffer. Add 20 ul of anti-PE microbeads (make 
sure beads are mixed well—do not vortex) per 80 ul of cells.  
Incubate for 15 minutes.  Fill tube with Miltenyi buffer and 
wash. 
XVI. Aspirate off supernatant and resuspend cells (2mls) for 
separation by MACs column or other means. (SEE BELOW) 
XVII. Take a small aliquot of separated cells for FACs.  
XVIII. Wash remaining cells. Aspirate off supernatant and 
resuspend in medium for generating DCs as per paper. 
 
MACS MAGNETIC SEPARATION 
I. Place column in the magnetic field of a suitable MACS Separator. For 
details see the respective MACS Column data sheet. 
II. Prepare column by rinsing with the 3 ml  Miltenyi buffer III. Apply cell suspension onto the column. 	  
IV. Collect unlabeled cells that pass through and wash column with the 3X 
3ml Miltenyi buffer. Collect total effluent; this is the unlabeled cell 
fraction. Perform washing steps by adding buffer three times. Only add 
new buffer when the column reservoir is empty.  
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V.  Remove column from the separator and place it on a 15 ml conical 
collection tube.	  VI. Pipette 5ml Miltenyi buffer onto the column. Immediately flush out the 
magnetically labeled cells by firmly pushing the plunger into the 
column.  (CD14+ MONOCYTES)	  
VII. (Optional) To increase the purity of the magnetically labeled cells, the 
eluted fraction can be enriched over a second MS or LS Column. 
Repeat the magnetic separation procedure as described in steps 1 to 6 by 
using a new column. 
VIII. Aliquot 10 ul of cells for counting (this is to determine how many cells 
will be plated per well for DC cell culture.  
IX. Aliquot 100ul for FACS determination of purity (compare to sample 
before magnetic separation. 
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APPENDIX C 
DIFFERENTIATION OF DCs FROM MONOCYTES 
 
Adapted from Agrawal et al. JI 2007 178: 6 
Medium  
R10 medium  
50 ng/ml rhGM-CSF 
10 ng/ml IL-4 
 
 
R10 M EDIUM        550 ml 
FBS (tested to be good for B cell cultures)    56 ml 
Penn/Strep         2.8 ml 
L-glutamine        5.6 ml 
2-ME (10-1 M stock) must have for B cells    560 ul 
RPMI         500 ml 
_________________________________________________________  
          ~560 ml 
 
Use of GM-CCSF 
Prospec GMCSF = $50 for 2 ug 
2ug is enough for 200 ml of medium 
Stock: Resuspend 2 ug in 1 ml = 2 ng/ul 
So add 25 ul of stock per ml of medium 
 
Use of IL-4 
Prospec IL-4 = $50 for 2 ug 
2ug is enough for 200 ml of medium 
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Stock: Resuspend 2 ug in 1 ml = 2 ng/ul 
So add 5 ul of stock per ml of medium 
Procedure: 
I. In 4 ml of Growth Media, add 100 ul of stock GM-CSF and 20ul 
IL-4 of medium 
II. Spin down cells in Miltenyi buffer after counting and completely 
aspirate supernatant. 
III. Plate cells at 1 X 105 cells per ml of culture medium in 24 well 
plate. 
IV. Remove and replace half of medium every 2 days for 6 days.    
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APPENDIX D 
EXPERIMENTAL SET-UP FOR DENDRITIC CELL MATURATION AND T-CELL 
FUNCTIONAL STUDIES 
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5.  STIMULATION OF DCS WITH FUSION PROTEINS 
 
 Conditions Remark 
1. No Stimulation Negative control 
2. CTB Use @10ug/ml  ( initial conc. is 166.6 ug/ml 
Therefore use @ 60.02 ul per ml of growth media 
3. INS Use @5ug/ml  (  stock soln is 0.5mg/ml) 
Therefore use at 10ul/ml 
4.GAD Use @5ug/ml  initial conc. is 166.6 ug/ml 
Therefore use @ 30.01 ul per ml of growth media 
5. CTB-INS  Use @20ug/ml  ( initial conc. is 2.5ug/ml) 
Therefore use @ 4 ul per ml of growth media 
6. CTB-GAD Use @10ug/ml (initial conc. is 166.6 ug/ml. Therefore use @ 60.02 ul per ml 
of growth media 
7. CTB + INS Use CTB  @10ug/ml  ( initial conc. is 83.3 ug/ml 
Therefore use @ 30.01 ul per ml of growth media 
Use @10ug/ml (stock soln is 0.5mg/ml). Therefore use at 5ul/ml 
8. CTB+ GAD Use CTB @10ug/ml (initial conc. is 166.6 ug/ml. Therefore use @ 30.01 ul 
per ml of growth media 
Use GAD @10ug/ml initial conc. is 166.6 ug/ml. Therefore use @ 30.01 ul per 
ml of growth media 
9. CTB-INS + CTB-GAD Use CTB-INS @10ug/ml (initial conc. is 2.5ug/ml). Therefore use @ 2 ul per 
ml of growth media 
Use CTB-GAD @10ug/ml (initial conc. is 166.6 ug/ml. Therefore use @ 
30.01 ul per ml of growth media 
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7. PMA+ Ionomycin Positive Control  
Use PMA at 10ng/mL of the cell suspension.  Ionomycin use at conc. 1mg/mL.  
 
a. Wash cells with PBS and spin down for 5 minutes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
209 
 
 
 
DC-T cell Co-culture setup 
 
a. Isolate T lymphocytes from cord blood using  anti CD3-PE beads 
b. Co-Culture DC-T cell (1:10 ratio) for 48 hrs 
Add anti Cd3/Cd28 activation beads to T cells except last sample 
 NO ST No stim DC only T cell only No stim DC+ T cell 
C         CTB-DC + T cell CTB-INS-DC + T cells CTB-GAD-DC + T 
cells 
LPS LPS-DC + T cells 
 
PMA+Iono- DC + T 
cells 
CTB + INS-DC 
+T cells 
CTB + INS-DC + T cells  CTB-INS + CTB-GAD+ 
T cells 
T cell only with no 
anti Cd3/Cd28 and 
PMa + Ionomycin 
 
After 48 hrs, remove media and wash cells with PBS 
 
Perform Golgi accumulation of Cytokine Assay 
1. Monensin on ice 
2. Remove plate from incubator after 48 hrs  
3. Add (1ul/ 200ul of media) of 3 mM monensin to each well 
4. Return to incubator for 6hr 
5. Final Concentrations are 15mM monensin (In addition to monensin, ADD PMA 
and Ionomycin to cells)  
After 6 hrs 
 
Harvest cells from each well and individually labeled FACs tube. 
 Wash in 2 ml PBS 
Spin down cells pour off supernatant and make sure that cells are in 10ul staining 
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wash.  
Transfer to 96-well plates for staining 
Surface Stain:  CD4PB, CD127PE, CD8 E-flour antibodies: 2 ul per; APC 
antibodies .5 ul per well.  
Incubate 15 minutes 
Wash with Staining Buffer and resuspend in 10ul staining buffer 
STAIN WITH 1:50 DILUTION OF SECONDARY SA-PE CY7 
• STAIN ISOTYPE CONTROL AT THIS TIME 
Incubate 15 minutes  
Intracellular cytokine staining following Surface staining using CALTAG 
METHOD 
Note: DO NOT RESUSPEND IN 1% PARAFORMALDEHYDE AFTER 
SURFACE STAINING   
1. Resuspend cells in 20ul of CALTAG reagent A (fixation solution). Pipette up and 
down. 
2. Incubate for 15 minutes at room temperature 
3. Wash cells with staining buffer (200ul, spin and flick) 
4. Add 20ul of reagent B (permeabilization solution) to each well. 
5. Add antibodies to each well and pipette up and down 
6. Incubate for 20 minutes at room temperature. 
7. Wash cells with staining buffer 
8. Resuspend in 200ul 1% paraformaldehyde 
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APPENDIX E 
LINEAGE MAP OF LUEKOCYTE DIFFERENTIATION 
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